Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients with multiple myeloma. The guideline provides recommendations for the treatment of both newly diagnosed and relapsed patients. Outcomes of interest include overall survival, progression-free survival, response rate, and quality of life.
Developer organization: German Guideline Program in Oncology
This is a clinical practice guideline for physicians who work on the prevention and treatment of colorectal cancer in the ambulatory and inpatient sector. The guideline provides recommendations for prevention, screening in asymptomatic populations as well as high risk populations, the role of endoscopy in the diagnosis of polyps and colorectal cancer, pre-operative diagnostics and surgery, adjuvant and neoadjuvant therapy, management of patients with metastases, palliative care and follow-up care.
Developer organization: British Society for Haematology
This is a clinical practice guideline for patients with primary mediastinal B-cell lymphoma. The guideline examines the staging, therapy, response assessment, relapse or refractory disease, and follow-up of these patients. The effect of chemotherapy on fertility and pregnancy is discussed, as well as thrombotic complications of superior vena cava obstruction (SVCO).
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The guideline discusses the clinical management of patients with CHL and NLPHL, focusing on patients who do not have serious intercurrent disease. Treatment options examined include chemotherapy, high dose therapy and autologous stem cell rescue (HDT/ASCR), and involved site radiation therapy (ISRT).
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.
Developer organization: American Society of Clinical Oncology
This clinical practice guideline is an endorsement of the College of American Pathologists' 2018 guideline titled Human Papillomavirus Testing in Head and Neck Carcinomas. The guideline examines the optimal way to test, apply, interpret, and report HPV and surrogate marker tests in head and neck carcinomas. Specific types of cancer discussed include oropharyngeal squamous cell carcinoma (OPSCC), oropharyngeal non-squamous cell carcinoma, and cervical nodal metastatic carcinomas of unknown primary site.
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for patients with Barrett's esophagus (BE), which is the only identifiable premalignant condition for esophageal adenocarcinoma (EAC). The guideline examines endoscopic eradication therapy (EET) and its role in the management of BE-related neoplasia. Outcomes of interest include progression to cancer, cancer-specific and all-cause mortality, adverse events, and recurrence rates.
Developer organization: British Society for Haematology
This is a clinical practice guideline for patients who have or are suspected of having primary central nervous system diffuse large B-cell lymphoma (PCNSL) located in the brain, spinal cord, cranial nerves, eyes or meninges. Specific topics discussed include diagnosis and imaging, treatment of primary CNS lymphoma, remission induction, consolidation treatment, follow-up, relapsed and refractory PCNSL, and neuropsychological assessments.
This is a clinical practice guideline for adult and pediatric patients with suspected or diagnosed well-differentiated neuroendocrine tumours (NETs). The guideline discusses the clinical utility of Gallium-68 positron emission tomography (PET) compared with PET / computed tomography imaging for the initial diagnosis, staging, re-staging, response evaluation, and routine surveillance of patients with NETs.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for patients with squamous cell cancers (SCC) of the anal canal and perianal region. The guideline specifically examines management options for premalignant and malignant squamous neoplasms of the anus and perianal region. Recommendations are provided regarding screening options, primary treatment, and surveillance for SCC and perianal squamous cell cancers.
This is a clinical practice guideline for patients with malignant pleural mesothelioma (MPM). The guideline provides recommendations on the investigation of suspected MPM, and the subsequent care and management of individuals with proven MPM. Topics of interest include the preferred investigation pathway of suspected cases of MPM, biomarkers, and the role of different treatments including chemotherapy.
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for the diagnosis and management of early and locally advanced breast cancer. The guideline provides recommendations on referral, diagnosis, preoperative assessment, genetic testing, surgical procedures, breast reconstruction, psychological support, and adjuvant therapies such as endocrine therapy and bisphosphonate therapy.
This is a clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines the diagnostic and staging criteria, treatment strategies, and follow-up and supportive care practices for these patients. First and second line treatment options are discussed for newly diagnosed, relapsed, and refractory disease.
This is a clinical practice guideline for adult patients with acute myeloid leukemia (AML). The guideline examines the diagnostic criteria and prognostic markers of acute myeloid leukemias. Different management options for acute myeloid leukemia are discussed, including chemotherapy, hematopoietic stem cell transplantation, and palliation.
This is a clinical practice guideline for patients who have been diagnosed with or are suspected of having advanced/metastatic prostate cancer. The guideline provides guidance on the staging, treatment, and follow up procedures for these patients. Topics of interest include radiotherapy techniques, the use of bone scans to assist in staging, and follow-up using active surveillance within a cancer clinic.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with diagnosed or suspected thyroid carcinoma. The guideline discusses the initial workup, diagnosis, staging, treatment, and follow up of patients with differentiated, papillary, follicular, medullary, and anaplastic thyroid carcinoma, as well as Hürthle cell carcinoma. Surgery, radiation therapy, and systemic therapy are discussed as treatment options.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adult patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Recommendations are provided for screening, staging, diagnosis, treatment, and follow-up. Treatment options discussed include debulking surgery, chemotherapy, and radiation therapy. Management of drug reactions is also discussed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with T-cell lymphoma. The guideline examines the diagnostic workup, staging, treatment, follow-up, and supportive care for the most common subtypes of T-cell lymphoma. These subtypes include peripheral T-cell lymphomas (PTCLs), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), mycosis fungoides (MF) and Sézary syndrome (SS), primary cutaneous CD30+ T-cell lymphoproliferative disorders, T-cell large granular lymphocytic leukemia (TGLL), adult T-cell leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (TPLL), and extranodal NK/T-cell lymphomas (ENKL), nasal type.
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, treatment and surveillance of B-cell lymphoma (BCL) in pediatric and adult patients. The guideline focuses on the most common B-cell lymphomas: follicular lymphoma (FL), marginal zone lymphomas (MZL), nodal MZL, splenic MZL, gastric MALT lymphoma, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), AIDS-related B-cell lymphoma, post-transplant lymphoproliferative disorders, and Castleman's disease. Additional consideration is paid to the classification systems used in NHL, the role of PET scans in assessment and staging, principles of radiation therapy, and supportive care considerations.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with breast cancer. The guideline examines staging, pathology assessment, and treatment approaches for pure noninvasive carcinomas, stage I, IIA, IIB, IIIA, or III invasive breast cancer, and stage IV metastatic or recurrent breast cancer. Special situations considered include Paget's disease, phyllodes tumours of the breast, breast cancer during pregnancy, inflammatory breast cancer, and axillary breast cancer.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline is for the management of squamous cell anal carcinoma. The guideline provides recommendations on staging, treatment, and follow-up. The effectiveness of treatment options such as surgery, chemotherapy, and radiation therapy are compared. Guidance is also provided on dosing regimens, treatment of recurrence, and surveillance following treatment of recurrence.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adolescent, young adult (AYA), and adult patients with acute lymphoblastic leukemia (ALL). The guideline reviews the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers, and provides recommendations on risk assessment and stratification for risk-adapted therapy, as well as treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL. The guideline also provides recommendations for supportive care.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with diagnosed or suspected thyroid carcinoma. The guideline discusses the initial workup, diagnosis, staging, treatment, and follow up of patients with differentiated, papillary, follicular, medullary, and anaplastic thyroid carcinoma, as well as Hurthle cell carcinoma. Surgery, radiation therapy, and systemic therapy are discussed as treatment options.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratification based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients who have been diagnosed with or are suspected of having malignant pleural mesothelioma. Recommendations are provided on diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodal therapy. Outcomes of interest include overall survival, progression-free survival, response rate, toxicity, quality of life (QoL), surgical complications, and diagnostic accuracy.
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults with newly-diagnosed or recurrent oesophago-gastric cancer. The guideline discusses clinical assessment, radical and palliative treatment, follow-up, nutritional support, and service organization. The primary outcomes of interest are increases in quality of life and survival.
This is a clinical practice guideline for adult patients who have been diagnosed with or are suspected of having lymphoma. The guideline discusses Hodgkin lymphoma, as well as the most common non-Hodgkin lymphomas (T-cell and B-cell). Recommendations are provided on diagnosis, staging, treatment, management, and follow up care.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with prostate cancer. The guideline examines various treatment options including active surveillance, radical prostatectomy, radiation therapy, other local therapies, androgen deprivation therapy, chemotherapy, and immunotherapy. It also discusses risk stratification, imaging, and estimates of life expectancy. Recommendations are provided for the initial diagnosis, clinical assessment, and staging evaluation, as well as for treatment, which are based on both the level of risk, and specific disease present.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.
Developer organization: American College of Radiology
This is a clinical practice guideline for women with epithelial ovarian cancers, specifically focusing on patients with type-2 ovarian cancers. The guideline examines diagnostic imaging methods, used for both staging and evaluating potential recurrence. Imaging modalities discussed include x-ray, magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT).
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with systemic mastocytosis (SM). The guideline provides recommendations on the diagnostic criteria for variants of SM, as well as for treatment and follow-up. Specific variants discussed include indolent SM, smoldering SM, aggressive SM, and SM with an associated hematological neoplasm.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.
This clinical practice guideline provides recommendations on the use of Mohs micrographic surgery (MMS) for adult patients diagnosed with skin cancer. MMS is compared to other surgical excision techniques, as well as other treatment modalities such as radiation. Guidance is provided on the indications and considerations for appropriate use of MMS, including disease stage, aesthetic outcomes, patient comorbidities, and patient preferences. Outcomes of interest include cure rate, recurrence rate, quality of life, and adverse events.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.
Developer organization: American College of Radiology
This is a clinical practice guideline for adults with muscle-invasive bladder cancer (MIBC). The guideline compares variations of imaging modalities for staging MIBC, such as x-ray, magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT). Outcomes of interest include diagnostic accuracy, sensitivity, specificity, and adverse health effects.
This is a clinical practice guideline for adult men with a suspicion or recent diagnosis of localized prostate cancer. The guideline examines staging, treatment options, and follow-up for these patients. Management is discussed for low, intermediate, and high-risk disease. Treatment options considered include variations of radical prostatectomy, brachytherapy, external beam radiotherapy, cryosurgery, and active surveillance.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with T-cell lymphoma. The guideline examines the diagnostic workup, staging, treatment, follow-up, and supportive care for the most common subtypes of T-cell lymphoma. These subtypes include peripheral T-cell lymphomas (PTCLs), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), mycosis fungoides (MF) and Sezary syndrome (SS), primary cutaneous CD30+ T-cell lymphoproliferative disorders, T-cell large granular lymphocytic leukemia (TGLL), adult T-cell leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (TPLL), and extranodal NK/T-cell lymphomas (ENKL), nasal type.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients who may be at high-risk for developing breast and ovarian cancer due to genetic/familial predispositions. The guideline provides recommendations on genetic risk assessment and genetic counseling, and specifically discusses the management of individuals with hereditary breast or breast/ovarian syndromes, including BRCA-related breast/ovarian cancer syndrome, Li-Fraumeni syndrome, and Cowden syndrome.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with prostate cancer. The guideline examines various treatment options including active surveillance, radical prostatectomy, radiation therapy, other local therapies, androgen deprivation therapy, chemotherapy, and immunotherapy. It also discusses risk stratification, imaging, and estimates of life expectancy. Recommendations are provided for the initial diagnosis, clinical assessment, and staging evaluation, as well as for treatment, which are based on both the level of risk, and specific disease present.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with breast cancer. The guideline examines the staging, pathology assessment, and treatment approach for these patients. Pure non-invasive carcinomas (stage 0), stage 1, 2A, 2B or 3A (T3, N1, M0) invasive breast cancer, stage 3 invasive breast cancer, and stage 4 metastatic or recurrent breast cancer are discussed. Special situations including Paget's disease, phyllodes tumours of the breast, breast cancer during pregnancy, inflammatory breast cancer, and axillary breast cancer are also considered.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bone cancer. The guideline focuses on chordoma, chondrosarcoma, Ewing sarcoma, osteosarcoma, and provides recommendations for treating giant cell tumour of the bone (GCTB). Workup, treatment, surveillance, and relapsed disease are discussed for each of the types of bone cancer mentioned. Staging, high-grade undifferentiated pleomorphic sarcoma of bone, and immunotherapy for bone cancer are also considered.
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults with suspected pancreatic cancer, or those with newly diagnosed or recurrent pancreatic ductal adenocarcinoma. The guideline provides recommendations for the monitoring of people with an inherited high risk of pancreatic cancer. Recommendations are also made for diagnosis, staging, psychological support, pain and nutrition management, as well as management for resectable, borderline resectable, and unresectable cancer.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, work-up, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for malignant pleural mesothelioma (MPM). The guideline examines the clinical management options for these patients, which include surgery, radiation therapy (RT), and chemotherapy. The potential for multimodal therapy is also addressed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults and children with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with esophageal or esophagogastric junction cancer. The guideline examines the initial workup, histological staging, primary treatment, and follow-up of both squamous cell carcinoma and adenocarcinoma. Treatment modalities discussed include surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratifications based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.
Developer organization: American Urological Association
This is a clinical practice guideline for the management of localized prostate cancer. The guideline provides a clinical framework stratified by cancer severity to guide the care plan and reviews management options including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU), and focal therapy. Shared decision making is highlighted, and guidance is provided on outcome expectations and management.
Developer organization: American Society of Clinical Oncology
This is a provisional clinical opinion (PCO) for chemotherapy-naive men with castration-resistant prostate cancer (CRPC). This PCO examines second-line hormonal therapy and provides recommendations on staging, treatment, follow-up, and palliative care for men with CRPC. Outcomes of interest include overall survival, adverse events, quality of life, and treatment efficacy (defined as response in prostate-specific antigen values).
This is a clinical practice guideline for adults with hepatocellular carcinoma (HCC). The guideline examines the goals of therapy, and provides recommendations for the treatment of patients with different stages of HCC, from very early stages to terminal stage. Outcomes of interest include rendering the patient free of disease, preventing recurrence, and improving quality of life.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.
Developer organization: German Society of Hematology and Medical Oncology (DGHO)
This is a clinical practice guideline for fever of unknown origin (FUO) in adult neutropenic patients. The guideline updates recommendations for diagnosis and empirical therapy of these patients in light of the challenges of antimicrobial stewardship. Specific recommendations are provided for taking down patient history and performing a physical examination, ordering chest radiograph, and taking nasal/pharyngeal (MRSA) or rectal (VRE) swabs.
Developer organization: European Association of Urology
This is a clinical practice guideline for the diagnosis and treatment of patients with testicular cancer. The guideline examines the pathology of the illness, staging and classification systems, diagnostic evaluation, prognosis, disease management, and follow-up. Topics of interest include diagnostic tools, treatment with chemotherapy, and discussion of quality of life and long-term toxicities after curative treatment.
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of muscle-invasive and metastatic bladder cancer. The guideline provides recommendations on prevention, staging, imaging, diagnosis, treatment, and follow-up. Treatment options such as neoadjuvant chemotherapy, radiotherapy, and radical surgery are discussed. Other topics of interest include risk factors, comorbidities, quality of life, and pelvic organ preservation techniques.
This is a clinical practice guideline for adult patients with desmoid tumours. The guideline provides recommendations for diagnosis, staging procedures, treatment, and follow-up. Treatment options including active surveillance, surgery, radiation therapy, and chemotherapy are examined. Topics of interest include desmoid tumours occurring during pregnancy, pain management, and rehabilitation.
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with cutaneous squamous cell carcinoma (cSCC). The guideline provides recommendations for the evaluation and management of patients with cSCC. Topics of interest include biopsy techniques and histopathologic assessment, tumour staging, surgical and non-surgical management, follow-up and prevention of recurrence, and management of advanced disease.
Developer organization: European School of Oncology
This is a clinical practice guideline for the management of patients with advanced breast cancer (ABC), including those with locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). The guideline provides recommendations for the management of these patients, and specifically discusses the use of chemotherapy, management of bone metastases, management of cancer related fatigue, as well as supportive and palliative care.
Developer organization: United States and Canadian Academy of Pathology
This is a clinical practice guideline for patients with colorectal cancer. The guideline examines tumour budding as a prognostic factor in these patients. The definition of tumour budding, clinical scenarios and tumour budding, H&E and immunohistochemistry for the tumour budding score, intratumoural and peritumoural budding, field number and size for the tumour budding score, cut-offs and continuous scale for the tumour budding score, and reporting tumour budding are all discussed.
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for adults who have been diagnosed with or are suspected of having basal cell carcinoma (BCC). The main focus of the guideline is on the most common approaches for the treatment of primary BCC, but it also includes recommendations on the treatment of recurrent tumours, appropriate biopsy techniques, staging, follow-up, and prevention of BCC.
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of urothelial carcinoma of the upper urinary tract (UTUC). The guideline provides recommendations on diagnosis, staging, treatment, and follow-up. Prognostic factors, predictors of survival and recurrence, as well as risk stratification are also discussed. Outcomes of interest include diagnostic accuracy, overall survival, recurrence rates, and adverse effects.
This is a clinical practice guideline for adult patients with soft-tissue sarcoma who are being considered for chemotherapy. The guideline provides recommendations for staging procedures and classifications, as well as treatment options based on staging results and other risk factors. Treatment options including surgery, systemic therapy, radiation therapy, and chemotherapy are discussed. Outcomes of interest include adverse events, performance status, progression-free survival, and overall survival.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the assessment of patients who are at high risk for colorectal cancer due to genetic or familial factors. The guideline provides recommendations for the management of patients with high-risk syndromes, including Lynch syndrome, familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome (PJS), Juvenile Polyposis Syndrome (JPS), Serrated Polyposis Syndrome (SPS), and other high-risk syndromes associated with colorectal cancer risk.
This is a clinical practice guideline for adult patients with early stage colon cancer. The guideline discusses diagnostic work-up, staging, and treatment options. Recommendations for adjuvant chemotherapy are presented, based on cancer stage.
This clinical practice guideline is an endorsement of the American Thyroid Association's 2015 guideline titled Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. The guideline provides recommendations on management of patients thyroid nodules and differentiated thyroid cancers. Topics include evaluation of thyroid nodules to determine the presence of malignancy, and management of differentiated thyroid cancer including surgery, radioactive iodine (RAI) therapy, hormonal therapy, external beam radiation therapy (EBRT), and systemic treatment.
Developer organization: The US Multi-Society Task Force on Colorectal Cancer
This is a consensus statement providing recommendations to assist health care providers with the appropriate management of patients with biallelic mismatch repair deficiency (BMMRD) syndrome, also called constitutional mismatch repair deficiency syndrome. The guideline outlines what is known about BMMRD, the unique genetic and clinical aspects of the disease, and reviews the current management approaches taken.
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for patients with thyroid cancer. The guideline examines the diagnosis, treatment, management, and follow-up of these patients. Topics of interest include a shift towards a standardized ultrasound/cytologic concordance system to guide investigation and management of thyroid nodules, acceptance of thyroid lobectomy as an option for many low risk thyroid cancers, acceptance of either no or lower dose radio-iodine treatment for many low risk thyroid cancers, and dynamic risk stratified follow-up for thyroid cancer.
This is a clinical practice guideline for the management of adult patients with adenocarcinoma of the pancreas. The guideline provides recommendations on diagnostic work-up, staging, and treatment options based on stage of cancer. Specific topics discussed include management recommendations for unresectable adenocarcinoma, and toxicity-associated dose modification. Outcomes of interest include adverse events, overall survival, and quality of life.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients who may be at high-risk for developing breast and ovarian cancer due to genetic/familial predispositions. The guideline provides recommendations on genetic risk assessment and genetic counseling, and specifically discusses the management of individuals with hereditary breast or breast/ovarian syndromes, including BRCA-related breast/ovarian cancer syndrome, Li-Fraumeni syndrome, and Cowden syndrome.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with melanoma. The guideline examines the use of sentinel lymph node (SLN) biopsy as a method for identifying nodal metastases, and provides recommendations on which patients should receive SLN biopsy based on the size and morphology of their melanoma. The guideline also discusses the appropriateness of completion lymph node dissection (CLND) as a method of treatment.
This is a clinical practice guideline for adults with Stage I to IV gastric cancer (specifically gastric adenocarcinoma) who are being considered for surgery. The guideline examines the optimal techniques to adequately stage gastric cancer, and the optimal techniques of gastric cancer surgery with curative intent. The guideline also considers indications for surgery for Stage IV gastric cancer in asymptomatic and symptomatic patients, and the relationship between surgical volumes and outcomes.
This recommendation report addresses "best practices" for prostate needle biopsies. Guidance is provided on the spectrum of prostate needle biopsy practices, including patient preparation, biopsy techniques, specimen submission to the laboratory, processing of the biopsy specimen, information to include on the requisition and pathology report, and operational issues. Facility requirements are also reviewed.
Developer organization: American Urological Association
This is a clinical practice guideline for patients with localized renal masses that are suspicious for renal cell carcinoma. The guideline discusses the evaluation, diagnosis, staging, and management of these renal masses. The management options discussed include partial nephrectomy, radical nephrectomy, thermal ablation, and active surveillance.
Developer organization: British Gynaecological Cancer Society
This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for merkel cell carcinoma. Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer along with the regional and distant metastatic rates of thick melanoma. This guideline provides recommendations for diagnosis and workup, staging, treatment, follow-up and recurrence. Treatment recommendations include surgery, sentinel lymph node biopsy, radiation therapy, and chemotherapy as possible options.
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.
Developer organization: International Pediatric Fever and Neutropenia Guideline Panel
This is a clinical practice guideline for the empirical management of fever and neutropenia (FN) in children with cancer, and those who have received hematopoietic stem-cell transplantation (HSCT). The guideline examines initial presentation, ongoing management, and empirical antifungal therapy. Topics of interest include risk stratification to define patients with high-risk invasive fungal disease (IFD), recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and empirical antifungal therapy in IFD low-risk patients with prolonged FN.
This recommendations report provides guidance on the investigation and management of suspected or proven pelvic and extra-pelvic gynecologic sarcomas. Recommendations are made on the use of pathology during investigation, while recommendations pertaining to treatment focus on surgery and adjuvant therapy. The guidance document also provides recommendations on a number of quality assurance measures to assess gynecologic sarcoma services.
Developer organization: American College of Radiology
This is a clinical practice guideline for the assessment of liver metastases. The guideline provides recommendations regarding the appropriateness of imaging modalities and the optimization of imaging parameters for specific clinical scenarios, including diagnosis, staging, and surveillance. Outcomes of interest include accuracy in characterizing and detecting liver lesions, length of examination, and potential adverse health effects, as well as surveillance sensitivity, specificity, and reproducibility.
Developer organization: American College of Radiology
This is a clinical practice guideline for adult men with prostate cancer or clinically suspected prostate cancer. The guideline examines the various imaging modalities that can be effectively used to manage these patients, during initial diagnosis, staging, and active surveillance. Variations of imaging modalities such as transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and computed tomography (CT) are discussed, and the appropriateness of different techniques is examined for different clinical situations.
Developer organization: American College of Radiology
This is a clinical practice guideline for adults and children with pancreatic ductal adenocarcinoma. Different variations of imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US) are discussed. The guideline examines the appropriateness of these techniques for two clinical situations: during initial staging before treatment, and following neoadjuvant therapy to evaluate tumour resectability for borderline resectable tumours.
Developer organization: American Urological Association
This is a clinical practice guideline for the management of non-metastatic muscle-invasive urothelial bladder cancer in adults. The guideline examines the initial evaluation, treatment, follow-up, and survivorship of affected patients, and discusses approaches to counseling and the role of patient preferences throughout. Specific treatment options considered include neoadjuvant and adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, and bladder preserving approaches such as maximal transurethral resection of bladder tumours, partial cystectomy, primary radiation therapy, and multi-modal bladder preserving therapy.
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for patients diagnosed with colon cancer. The guideline examines the evaluation, staging, and treatment of these patients. Surgical treatment of the primary tumour is discussed, as well as treatment of tumour-related emergencies, management of stage 4 disease, management of locoregional recurrence, documentation, and adjuvant therapy.
Developer organization: European Association of Urology
This is a clinical practice guideline for adult patients with renal cell carcinoma (RCC). The guideline examines the staging, diagnosis, prognosis, treatment, and follow-up of these patients. Management recommendations are provided for treating localized RCC, locally advanced RCC, advanced/metastatic RCC, and recurrent RCC. The epidemiology, etiology, and pathology of RCC are also discussed.
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of non-muscle-invasive bladder cancer. Recommendations are provided for diagnosis, staging, treatment, and follow-up. The guideline also discusses how to predict the short-term and long-term risks of disease recurrence and progression, as well as the stratification of patients into risk groups. Treatment options are presented based on these risk groups. Management of side effects is also discussed.
Developer organization: British Gynaecological Cancer Society
This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.
Developer organization: Spanish Society of Nuclear Medicine and Molecular Imaging
This is a clinical practice guideline on the role and appropriateness of fluorodeoxyglucose positron emission tomography - computed tomography (18F-FDG PET/CT) for initial breast cancer staging and its therapeutic and prognostic impact. Recommendations are stratified by risk, and outcomes of interest include sensitivity, specificity, change in stage compared to staging done by conventional imaging, prognosis, and costs. The guideline also addresses the association of metabolic information with biology and prognosis.
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline examines the clinical management of RCC, including diagnosis, treatment, and follow up. The primary outcomes of interest are survival, recurrence, and quality of life.
This is a clinical practice guideline for adult patients with four or fewer brain metastases. The guideline examines the important prognostic factors for assessing and managing these patients, the role of surgery and radiotherapy in the management of oligometastatic disease, and the appropriate follow-up and surveillance strategy. Treatments considered include whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS), both alone and in conjunction.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.
Developer organization: European Association of Urology
This is a clinical practice guideline for adult patients with prostate cancer. The guideline examines the screening, diagnosis, staging, treatment, and follow-up of these patients. Treatment options considered include deferred treatment, radical prostatectomy, definitive radiotherapy, and hormonal therapy. Management of metastatic prostate cancer, prostate cancer in older men, prostate-specific antigen-only recurrence after treatment, and castration-resistant prostate cancer are also discussed, as well as the epidemiology and etiology of prostate cancer, and quality of life outcomes.
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with primary urethral carcinoma (UC). The guideline provides recommendations on the diagnosis and treatment of UC. Staging and classification systems for UC are also discussed. Outcomes of interest include detection rate, overall survival, complications, and toxicity.
A clinical practice guideline on the diagnosis, staging, treatment and management of adult patients who are suspected of having, or have been diagnosed with, chronic myelogenous leukemia (CML). Treatment options examined include the use of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, as well as allogeneic stem cell transplant (SCT) and Interferon-a (IFNa). Special consideration is paid to the use of TKIs in the treatment of elderly patients with CML.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.
Developer organization: French Dermatological Society
This is a clinical practice guideline for the management of stage I to III melanoma in adult patients. The guideline discusses classification, resection margins, sentinel node biopsy, adjuvant treatments, initial work-up, follow-up, and the role of molecular biology tests. The guideline also compares the recommendations provided by other European guidelines and addresses any disparities in recommendations.
Developer organization: European Thyroid Association
This is a clinical practice guideline for patients with thyroid nodules. The guideline provides recommendations on molecular fine-needle aspiration (FNA) cytology diagnostics, and discusses topics such as the use of microarray gene expression classifier (GEC) tests, mutation panel assessments, and targeted next-generation sequencing (tNGS). Outcomes of interest include reductions in diagnostic lobectomies, and improved surgical decision-making.
Developer organization: American Society of Clinical Oncology
This clinical practice guideline focuses on molecular biomarker testing for patients with early and advanced colorectal cancer. The recommendations are intended to help establish standard molecular biomarker testing, guide decisions on whether or not to use epidermal growth factor receptor (EGFR)-targeted therapy, and to ensure that the most effective and advance personalized care is delivered to patients.
This is a clinical practice guideline for women presenting with suspicious adnexal masses, either symptomatic or asymptomatic. The guideline examines the optimal strategies for preoperative identification of adnexal masses that are suspicious for ovarian cancer, and the most appropriate surgical procedures for those identified.
A clinical practice guideline for the management of adult onset sarcoma. The guideline examines the diagnosis, staging, treatment, and follow-up options for sarcoma. Imaging modalities for the purpose of diagnosis and staging are compared, while the importance of multidisciplinary care and the effects of delayed referrals to specialists are discussed. In addition, pre-operative and post-operative radiotherapy are compared, and the guideline also examines adjuvant and systemic chemotherapy, as well as surgical procedures. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of April 23, 2018.
Developer organization: American College of Obstetricians and Gynecologists
This is a clinical practice guideline for patients with suspected or incidentally diagnosed adnexal masses. The guideline discusses the use of ultrasonography and serum marker testing during initial evaluation, which findings indicate malignant versus benign masses, and the appropriate situations for surgery versus observation. Specific recommendations are also provided for adolescents and pregnant women.
Developer organization: German Society of Hematology and Medical Oncology (DGHO)
This is a clinical practice guideline for patients with hematological malignancies including allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients. The guideline provides recommendations for the management of central nervous system infections in these patients. Specific topics addressed include epidemiology and causative agents, pathogenesis, prophylaxis, diagnosis, antimicrobial treatment, and adjunctive treatment.
Developer organization: National Institutes of Health
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes: follicular lymphoma, MALT lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and peripheral T-cell lymphoma. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Developer organization: Belgian Health Care Knowledge Centre
This clinical practice guideline provides recommendations for the diagnosis, treatment, and follow-up of epithelial ovarian cancer. This guideline covers: carcinoma of the ovary, fallopian tube and primary peritoneal carcinoma; epithelial carcinoma, e.g. serious, mucinous, clear cell or endometrioid histology; borderline and invasive disease, diagnosis and first-line treatment; and follow-up after treatment. Recommendations consider patient values and preferences when treated for ovarian cancer.
A clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines diagnosis, staging, and treatment of newly diagnosed, relapsed, and refractory leukemia. Outcomes of interest include progression-free survival, reduced adverse events, and treatment response.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Non-Hodgkin's Lymphomas (NHL). The guideline focuses on recommendations for diagnostic workup, treatment, and surveillance strategies for the most common subtypes of NHL, in addition to a general discussion on the classification systems used in NHL and supportive care considerations. The most common NHL subtypes that are covered in the guideline are: Mature B-cell lymphomas, Mature T-cell and NK-cell lymphomas, Post Transplant Lymphoproliferative Disorders (PTLD), and Castleman's Disease.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for multiple myeloma. The guideline addresses diagnosis, treatment, and follow-up care. It offers specific recommendations for primary therapy, surveillance and follow-up tests for solitary plasmacytoma, smoldering (asymptomatic) myeloma, active (symptomatic) multiple myeloma, as well as for transplant and non-transplant candidates.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumors, and osteosarcoma. Surveillance and relapse is also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations for the diagnosis and treatment of acute myeloid leukemia (AML). Induction therapy and post-remission (consolidation) therapy are reviewed with recommendations stratified by risk and age. Specific recommendations are provided for the management of acute promyelocytic leukemia (APL). The guideline also discusses therapy for relapse, evaluation and treatment of CNS leukemia, and supportive care.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adult patients with non-small cell lung cancer. The guideline provides updated recommendations around prevention and screening, evaluation and staging, treatment, and follow up care. Areas of focus are discussed with recognition that much progress has been made in regards to screening, minimally invasive techniques for diagnosis and treatment, advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), and targeted therapies.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.
This clinical practice guideline reviews the use of sentinel node biopsy (SLNB) as a diagnostic tool for adult patients with malignant melanoma. Topics of discussion include indications and contraindications of SLNB, pathological examination of the sentinel nodes, and indications for therapeutic node dissection and recommended extent of dissection. The use of ultrasound-guided fine-needle aspiration is also discussed. Outcomes of interest include test sensitivity, specificity, and positive and negative predictive value, as well as rate of nodal recurrence and survival.
Developer organization: Sociedade Brasileira de Dermatologia
A clinical practice guideline for patients with primary cutaneous melanoma. The guideline examines diagnosis, treatment, and follow-up including preventive excision and body mapping. Outcomes of interest include melanoma-specific survival and morbidity.
This is a clinical practice guideline for magnetic resonance imaging (MRI) for pre-treatment local staging of prostate cancer. The use of MRI for pre-treatment local staging is juxtaposed with the ways in which prostate cancer is conventionally detected which includes prostate-specific antigen (PSA) screening, digital rectal examination (DRE), and biopsy-confirmed diagnosis by transrectal ultrasonography (TRUS). The guideline therefore explores the performance and diagnostic accuracy of MRI, as well as the impact of pre-treatment local staging by MRI on patient on patient outcomes, biochemical recurrence, changes in treatment planning (including nerve- sparing surgery), changes in stage classification, and surgical margin status in men with newly diagnosed biopsy-confirmed prostate cancer who are under consideration for radical treatment.
A clinical practice guideline for women with stage I ovarian cancer. The guideline examines adjuvant therapy, primarily systemic therapies, in relation to surgical staging. Outcomes of interest include overall and disease-free survival.
Developer organization: American College of Radiology
This clinical practice guideline provides recommendations on the diagnosis and treatment of locally advanced and borderline resectable pancreatic cancer. Radiotherapy alone is compared to chemoradiation for treatment of locally advanced disease, and preoperative therapy for borderline resectable disease is discussed. The guideline reviews neoadjuvant systemic therapy followed by local treatment and provides recommendations on chemotherapy regimes. Outcomes of interest include progression-free survival, median survival, 1-year survival, and local control.
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline provides recommendations on the investigation, treatment, and follow-up care of patients aged 16 years and older with cancer of the upper aerodigestive tract. HPV-related disease and less common upper aerodigestive tract cancers including carcinoma of the nasopharynx or paranasal sinuses, unknown primary of presumed upper aerodigestive tract origin, and mucosal melanoma, are also reviewed. Additionally, recommendations are provided on optimizing rehabilitation and function. Outcomes of interest include prevalence, predictive value, sensitivity, specificity, local control, survival (overall, progression-free), treatment-related morbidity and mortality, and resource use, among others.
Developer organization: Spanish Society of Medical Oncology
This is a clinical practice guideline for the diagnosis, treatment and follow-up of patients with gastrointestinal stromal tumours (GISTs). The guideline discusses the diagnosis of GISTs using radiology, histology and molecular biology, while also providing recommendations for the treatment of both localized and advanced disease. Surgery, adjuvant and neoadjuvant treatment options are specifically examined.
Developer organization: Chinese Glioma Cooperative Group
This is a clinical practice guideline for adults with diffuse gliomas. Diagnosis, as well as treatment methods including chemotherapy, radiation therapy, and surgical procedures are discussed. The guideline provides general recommendations, as well as specific recommendations for low grade gliomas (WHO grade II), anaplastic gliomas (WHO grade III), and glioblastoma (WHO grade IV).
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for patients undergoing endobronchial ultrasound (EBUS) for the real-time guidance of transbronchial needle aspiration (TBNA) of mediastinal and hilar structures and parabronchial lung masses. The guideline discusses the technical aspects of linear EBUS-TBNA, including patient factors (e.g. sedation), procedural aspects (e.g. ultrasonographic features of lymph nodes, needle size, number of needle passes, use of suction, and presence of rapid on-site cytologic evaluation), and proceduralists' aptitude (i.e. training) are specifically addressed.
This is a clinical practice guideline for adults with low-grade gliomas (LGGs). The guideline examines the diagnosis, prognosis, and treatment of these patients. Treatment modalities discussed include surgery, radiation therapy, and chemotherapy.
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines appropriate management and follow-up strategies for different stages of the two main histological types of testicular GCTs: seminomas and nonseminomas. Outcomes of interest include recurrence and overall survival.
This is a clinical practice guideline for patients with neoplasms causing biliary obstruction. The guideline examines the management of malignant biliary obstructions, including diagnostic work-up and treatment options. Recommendations are provided based on factors such as the resectability and location of the obstruction. Outcomes of interest include improved quality of life (QOL) and prolonged survival.
This is a clinical practice guideline for the clinical management of malignant melanoma with the aim of improving the standard of care received by this patient population. The guideline provides recommendations on referral to surgeons and associated wait times, procedures (e.g., biopsy), tumour markers, and adjuvant therapies.
Developer organization: American Urological Association
This is a clinical practice guideline for patients with non-muscle invasive bladder cancer. Recommendations are provided on diagnostic procedure, risk stratification, variant histologies, urine markers, and treatment options including TURBT/Repeat resection, intravesical therapy, BCG/maintenance, and chemotherapy BCG combinations. BCG relapse and salvage regimens are reviewed as is the role of cystectomy and cystoscopy. Additionally, recommendations are provided for risk adjusted surveillance and follow-up strategies.
Developer organization: American College of Radiology
This is a clinical practice guideline for recurrent Hodgkin lymphoma. The guideline provides recommendations for the treatment of patients with early relapsed or progressive disease. Areas of focus include: stem cell transplantation, the role of radiation therapy, and chemotherapy.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for soft tissue sarcoma. The guideline examines diagnosis, treatment and follow up. Various stages are addressed, as well as a various treatment options and disease progression. Guidance is presented for specific issues (e.g., gastrointestinal stromal tumors).
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for chronic lymphocytic leukemia/ small lymphocytic lymphoma. This guideline provides recommendations relating to diagnosis, prognostic factors, workup, staging, and response criteria. It also provides recommendations as they pertain to treatment options, which include discussions about first-line therapy, relapsed or refractory therapy, as well as assessment of functional status and comorbidity.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.
This is a clinical practice guideline for the investigation and diagnosis of suspected lung cancer and referral for treatment, particularly for patients residing in Nova Scotia. The guideline reviews the investigation process from initial presentation to treatment referral. Topics include principles of communication between patient-provider and among providers throughout the diagnostic process, standards for initial investigation, appropriate use of imaging (CT, MRI, PET, bone scan) and biopsy and laboratory testing, as well as recommendations regarding treatment referral upon diagnosis. Referrals to diagnostic specialists (thoracic surgery or respirology) and to psychosocial and supportive care are also reviewed.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.
Developer organization: American Society for Gastrointestinal Endoscopy
This clinical practice guideline discusses the evaluation and treatment of patients with suspected solid pancreatic neoplasia. The guideline reviews presentation and clinical evaluation of pancreatic neoplasia, and provides an overview of radiologic and endoscopic modalities for adenocarcinoma of the pancreas, neuroendocrine tumours (NETS) of the pancreas, solid pseudopapillary tumours (SPTs), metastatic disease, and lymphoma. Screening for pancreatic cancer is also discussed. Outcomes of interest include sensitivity and specificity, as well as adverse events.
Developer organization: Spanish Society of Medical Oncology
This is a clinical practice guideline for patients with soft-tissue sarcoma (STS). The guideline examines the therapeutic decision-making processes used for the management of STS in order to improve patient care. Recommendations are provided for staging, diagnosis, and treatment.
Developer organization: European Association of Neuro-Oncology
This is a clinical practice guideline for patients with meningiomas. Recommendations are provided regarding diagnosis, including radiological methods used, collection and storage of tissue, and histological verification. Different treatment and follow-up recommendations are also discussed, based on which World Health Organization (WHO) grade the meningioma is classified as (i.e. WHO grades I-III).
This is a clinical practice guideline for the prevention and treatment of cancer-associated venous thromboembolism (VTE). The guideline provides recommendations for the appropriate workup to search for occult malignancy in patients with idiopathic VTE, the identification of high-risk cancer patients for primary thromboprophylaxis, the appropriate immediate and long-term treatment for people with cancer diagnosed with acute thromboembolism, the appropriate duration of anticoagulation and the appropriate treatment strategy in patients with recurrent VTE on anticoagulation.
Developer organization: Clinical Oncological Society of Australia
This is a clinical practice guideline for teleoncology models of care. Teleoncology seeks to offer solutions to some of the access issues faced by patients and health professionals from regional, rural and remote communities around the world. The focus of the guideline is shaped by a number of clinical questions that include: what teleoncology models of care are available to health services in Australia and overseas; what models of care for teleoncology are available to nursing services; what models of care for teleoncology are available to allied health services; is teleoncology as effective as standard oncology care for the screening of cancer; is teleoncology as effective as standard oncology care for the diagnosis of cancer; is teleoncology as effective as standard oncology care for the treatment of cancer; and is teleoncology as effective as standard oncology care for the palliative care of cancer patients.
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients with rectal cancer. The guideline provides recommendations on use of MRI for staging, optimal surgical techniques for patients with T1-T2 anal cancer with comparisons made between local resection or transanal endoscopic microsurgical resection and radical resection, and the use of adjuvant chemotherapy for patients who have received neoadjuvant radiotherapy (RT). Outcomes of interest include survival (overall, disease free, metastasis-free, local recurrence free), and quality of life.
A clinical practice guideline for patients with lymphoma, including small lymphocytic leukemia (SLL)/chronic lymphocytic leukemia (CLL), Waldenstroms, marginal zone lymphoma, and cutaneous lymphoma. The guideline examine the use of PET/CT, primarily for staging and response assessment. Outcomes of interest include survival, quality of life, and appropriate use.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the screening, diagnosis, staging, and treatment of neuroendocrine tumors. This guideline provides recommendations on issues including: multiple endocrine neoplasia, surveillance of resected neuroendocrine tumors of the gastrointestinal tract, lung, and thymus, and genetic counseling/testing in pheochromocytomas/paragangliomas. Most of the guideline sections pertain to well-differentiated, low- to intermediate-grade tumors, although poorly differentiated/high-grade/large or small cell carcinomas are also addressed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, and primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for the treatment of patients with metastatic pancreatic cancer. This clinical practice guideline addresses six overarching clinical questions: After a histopathologic confirmation of pancreatic adenocarcinoma diagnosis, what initial assessment is recommended before initiating any therapy for metastatic pancreatic cancer? What is the appropriate first-line treatment of patients with metastatic pancreatic cancer? What is the appropriate therapy for patients with metastatic pancreatic cancer who experience either disease progression or intolerable toxicity with prior regimens for metastatic pancreatic cancer? When should the concept of palliative care be introduced? For patients with metastatic pancreatic cancer, what are the recommended strategies for relief of pain and symptoms? What is the recommended frequency of follow-up care/surveillance for patients with metastatic pancreatic cancer?
This guideline discusses the clinical standards of care for the treatment of rectal cancer in Nova Scotia with all aspects of rectal cancer care covered, from diagnosis to survivorship and/or palliation. This includes recommended standards for professionals involved in care, pretreatment investigations, and surgical, neo-adjuvant, and adjuvant treatments. Other topics covered include lynch syndrome screening and referral to medical genetics. Psychosocial health services and supportive care recommendations are also reviewed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for small cell lung cancer and lung neuroendocrine tumours. Diagnosis, staging, prognostic factors, treatment and surveillance are reviewed. Treatment options include chemotherapy, with special topics of discussion including elderly patients and second- and third-line therapies, radiotherapy (thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy), and surgery. Outcomes of interest include survival (disease free, overall, progression-free), response rates, and treatment toxicity.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup, staging, and treatment for both noninvasive and invasive breast cancer. Special considerations include phyllodes tumor, Paget's disease, breast cancer during pregnancy, and inflammatory breast cancer. Treatment recommendations for invasive cancer are stratified by tumor receptor status and stage. Fertility and birth control is also discussed.
This is a clinical practice guideline for the staging and treatment of colorectal cancer. The guideline focuses on surgical and pathological considerations for the resection of colorectal cancer and provides recommendations on the technique and extent of resection, as well as the reporting of resection results. Outcomes of interest include overall survival, disease-free survival, recurrence rates, and margin status.
Developer organization: German Society of Hematology and Oncology (DGHO)
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline discusses diagnosis, treatment, and follow-up, and provides specific recommendations on topics such as the primary treatment of RCC without metastases, systemic treatment for metastatic RCC, neoadjuvant/adjuvant therapy, as well as the resection and radiotherapy of metastases.
Developer organization: American College of Radiology
This guideline reviews clinical presentation and patient evaluation, prognostic factors, principles of management, and treatment outcomes for patients with nasal cavity and paranasal sinus cancers. Surgery, radiotherapy, and chemotherapy are discussed as treatment options. Special topics of interest include the management of cervical lymph nodes and the management of unusual pathologies of nasal cavity cancers, namely esthesioneuroblastoma and sinonasal undifferentiated carcinoma.
Developer organization: American College of Radiology
This is a clinical practice guideline for the staging of testicular malignancy. Recommendations are made with consideration of the following variant: staging testis tumour, diagnosed by orchiectomy. The guideline also discusses tumour markers and provides an overview of imaging modalities.
A clinical practice guideline for patients with chronic lymphocytic leukemia (CLL), monoclonal B cell lymphocytosis (MBL) and small lymphocytic lymphoma (SLL). The guideline examines clinical assessment, staging, and treatment including supportive therapy and potential complications. Outcomes of interest include long-term remission, increases in secondary malignancies, and disease progression.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for myelodysplastic syndromes (MDS). The guideline provides an update to recommendations on standard approaches to the diagnosis and treatment of MDS in both children and adults. The guideline discusses evaluation and prognostic stratification, Topics of interest include prognostic stratification, evaluation of related anemia and treatment of symptomatic anemia, and supportive care. Molecular abnormalities in MDS and comorbidity indices are also discussed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.
Developer organization: American Society of Clinical Oncology
This clinical practice guideline provides evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer (LAPC). The guideline addresses a number of key clinical questions including: what initial assessment is recommended before initiating therapy for LAPC; what is the appropriate initial treatment approach for people diagnosed with LAPC; and for people with LAPC, what are the recommended strategies for relief of pain and symptom burden.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, upper urinary tract urothelial carcinomas (UTUCs). The guideline reviews diagnostic assessment, staging, treatment, and follow-up. Treatment recommendations are provided based on whether the disease is localized or advanced and include radical nephroureterectomy, conservative surgery, adjuvant topical agents, chemotherapy, and radiotherapy. Outcomes of interest include risk factors, sensitivity and specificity of diagnostic tests, survival (recurrence-free, disease-free, and overall), disease progression, morbidity, and mortality.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients with early-stage breast cancer. The guideline provides recommendations regarding the use of sentinel node biopsy (SNB) for determining the extent to which patients' breast cancer has spread. Outcomes of interest include when to use SNB, and potential benefits and harms associated with SNB.
Developer organization: American College of Radiology
This is a clinical practice guideline for the pretreatment staging of colorectal cancer. Recommendations are made with consideration of two different variants of colorectal cancer: 1. rectal cancer, locoregional staging, and 2. colorectal cancer, staging for distant metastases. The guideline provides recommendations as to the appropriate imaging modalities to be used in the initial staging of colorectal cancer.
Developer organization: National Institute for Health and Care Excellence
This guideline is for adult patients over 16 years of age with suspected, newly diagnosed, or relapsed myeloma. The guideline provides recommendations on laboratory and imaging investigations, management of newly diagnosed myeloma, managing acute renal disease caused by myeloma, preventing and managing complications, disease monitoring, and managing relapsed myeloma. Recommendations are also provided on service organization. Outcomes of interest include time to biochemical and/or clinical progression, overall survival, adverse events, quality of life and resource use.
Developer organization: European Association of Urology
This is a clinical practice guideline for male patients diagnosed with or suspected of having prostate cancer. The guideline reviews classification and staging, diagnostic evaluation, disease management, and follow-up care. Side effects of local treatment and health-related quality of life in prostate cancer survivors are also discussed. Outcomes of interest include overall survival, cancer-specific survival, development of metastatic disease, sensitivity and specificity of diagnostic procedures, and side effects of treatment.
Developer organization: American Thyroid Association
This is a clinical practice guideline for adult patients with thyroid nodules and differentiated thyroid cancer (DTC). The guideline provides recommendations on initial management of thyroid cancer including screening, staging, risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine, as well as long-term management including surveillance techniques, management of recurrent and metastatic disease, and consideration for clinical trials and targeted therapy. The evaluation and diagnostic approach for thyroid nodules is also discussed, including a review of indications for fine-needle aspiration biopsy and interpretation of results, as well as use of molecular markers and management of benign thyroid nodules. Outcomes of interest include survival, recurrence, sensitivity and specificity.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the diagnosis, staging, and treatment of thyroid carcinoma. Recommendations are stratified by histologic type, namely papillary, follicular, Hürthle cell, medullary, and anaplastic. Primary treatment options and assessment and management after initial treatment is reviewed. Recurrent or persistent disease is also discussed.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Hodgkin lymphoma. The guideline discusses the clinical management of patients with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), focusing exclusively on patients from post adolescence through the seventh decade of life who do not have serious intercurrent disease. Areas considered and discussed within the guideline include: staging and prognosis, the role of PET scans, treatment, principles of radiation therapy, and follow-up after completion of treatment.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on esophageal and esophagogastric junction (EGJ) cancers, including: a review of hereditary cancer predisposition syndromes associated with increased risk for esophageal and EGJ cancers, staging and pathology, imaging, and treatment including surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies. Surveillance, management of metastatic, or recurrent cancer, and best supportive care are also discussed. Special topics of interest include treatment and surveillance options for patients with Barrett's esophagus, and suggested strategies to help alleviate the current problems associated with leucovorin shortage.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline provides evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Key recommendations are guided by questions including: what initial assessment is recommended before initiating any therapy for potentially curable pancreatic cancer; what is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone a resection of their primary tumor; and when should palliative care services be initiated for people with pancreatic cancer that is potentially curable by surgery.
This is a clinical practice guideline for patients over 18 years of age with esophageal cancer, including both squamous cell and adenocarcinoma. The guideline provides recommendations on diagnostic work-up, staging, treatment options for potentially curable cancer stratified by stage, and management options for incurable cancer. Esophagectomy, endoscopic therapy, primary chemoradiotherapy, radiotherapy, pre-operative chemoradiotherapy followed by esophagectomy and pre-operative chemotherapy are discussed, as well as supportive care. Outcomes of interest include survival (overall, progression-free, 5-year), morbidity, toxicity, and rate of sudden death.
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline reviews the use of pre- and post-operative therapy including chemotherapy and radiotherapy as treatment options. Outcomes of interest include survival (overall, cause-specific), quality of life, acute and late toxicities, and postoperative morbidity (within 30 days of surgery).
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline for the management of diffuse large B-cell lymphoma. Recommendations include consideration of: prognostic factors, early stage disease, advanced stage disease, relapsed/refractory disease in the transplant-eligible patient, HIV-associated DLBCL, management of the elderly, frail or unfit patient with DLBCL, and follow-up.
This is a clinical practice guideline addressing lymphoma in the adult population. The guideline focuses on diagnosis and pathology, staging, and treatment of Non-Hodgkin Lymphomas, Hodgkin Lymphoma, HDCT and hematopoietic stem cell transplantation for lymphoma. Supportive and follow-up care is also addressed. The guideline updates the 2015 guideline of the same title.
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline for patients with suspected uterine neoplasms. The guideline examines surveillance, diagnostic assessment, and treatment focusing primarily on surgical interventions and systemic therapy. Outcomes of interest include long-term survival and reproductive sparing.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the evaluation, treatment, and management of thymomas and thymic carcinomas. The guideline considers surgical resection, systemic therapies, and radiation therapies for both mediastinal and thymic masses.
Developer organization: American College of Radiology
This is a clinical practice guideline for women with vulvar carcinoma. The guideline examines the appropriate use of adjuvant therapy in these patients, following primary surgical treatment. Adjuvant radiation, including dose, fields, and technique, as well as adjuvant chemotherapy, were discussed as potential treatment options. In addition, the guideline examines the appropriateness of different imaging techniques, such as magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT), for the staging of vulvar carcinoma.
A clinical practice guideline for adult patients with potentially curable esophageal carcinoma. The guideline examines diagnosis with FDG-PET/CT, staging, and treatment options including chemoradiotherapy and brachytherapy. Outcomes of interest include staging accuracy and treatment response.
This is a clinical practice guideline for the evaluation, diagnosis and management of a suspicious lateral neck mass in adults. Use of history and physical exam, X-ray, CT scan, and fine needle aspiration biopsy (FNAB) are discussed along with urgency of referral depending on results. Additionally, the guideline addresses the diagnosis or suspicion of lymphoma, as well as appropriate use of open biopsy.
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for the use of GI endoscopy in the evaluation and treatment of pancreatic neoplasms. Diagnosis by endoscopic ultrasound (EUS) is discussed, as is use of EUS-guided-fine needle aspiration (FNA) to determine cytology, chemistries and tumour markers such as CEA, as well as cyst fluid DNA and molecular analysis. Other topics of discussion include emerging techniques for cyst evaluation, adverse events fro EUS, diagnosis by ERCP (Endoscopic Retrograde Cholangio-Pancreatography), and endoscopic treatment of cystic lesions.
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of renal cell carcinoma. The guideline examines the diagnosis, staging, treatment, and follow-up of renal cell carcinoma, with treatment recommendations stratified by disease stage. Therapeutic strategies are also discussed. Outcomes of interest include overall survival, cancer-specific survival, recurrence-free survival, and quality of life.
Developer organization: European Association of Urology
This clinical practice guideline provides recommendations for urothelial carcinomas of the upper urinary tract. The guideline covers epidemiology, etiology, and pathology, staging, diagnosis, prognosis, disease management, and follow-up. Issues addressed in the guideline include: risk factors, symptoms, imaging, preoperative factors, predictive tools, and management for both localized and advanced disease.
Developer organization: European Association of Urology
This is a clinical practice guideline for non-muscle-invasive bladder cancer (Ta, T1 and CIS). The guideline covers staging and classification systems, diagnosis, disease recurrence, management, and follow-up. Issues addressed include: imaging, chemotherapy, and biopsy.
Developer organization: European Association for Neuro-Oncology
This is a clinical practice guideline for immunocompetent adults with primary CNS lymphoma. The guideline provides consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, the guideline addresses aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients.
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for the diagnosis, staging, and treatment of oropharyngeal cancer. The guidelines provide recommendations on staging for primary tumour, regional lymph nodes, and distant metastases; management of invasive carcinoma of oropharynx, locally advanced resectable disease; post-operative adjuvant therapy options, post chemoradiation or post radiation evaluation; salvage therapy; radiation therapy; concurrent chemotherapy; and management of residual disease, loco-regional recurrent or distant metastases.
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for the diagnosis, treatment, and follow-up of oropharyngeal, hypopharyngeal and laryngeal cancers. The guideline examines preferred locoregional staging methods and treatment options including an emphasis on interprofessional care. Outcomes of interest include limited evidence for the benefits of surgical treatment in some cases and some evidence that primary chemotherapy may provide some benefit over radiotherapy.
Developer organization: American Thyroid Association
These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules. Recommendations for the evaluation, treatment, and follow-up of children and adolescents with differentiated thyroid cancer (DTC) are outlined and include preoperative staging, surgical management, postoperative staging, the role of radioactive iodine therapy, and goals for thyrotropin suppression. Management algorithms are proposed and separate recommendations for papillary and follicular thyroid cancers are provided.
Developer organization: Ministry of Health Malaysia
A clinical practice guideline for the management of female patients with cervical cancer. The guideline examines diagnosis, staging, treatment including surgery and adjuvant therapy, and follow up. Outcomes of interest include fertility preservations and improved quality of life through hormonal replacement therapy during follow up.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline is for patients diagnosed with or suspected of having melanoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Follow-up care is also discussed, including topics such as management of suboptimal Vitamin D levels and concurrent drug therapies. Outcomes of interest include survival (overall, disease free, melanoma specific), and adverse events (acute toxicity, wound/sensory complications).
This clinical practice guideline provides recommendations on management of prostate cancer, including diagnosis and screening, management stratified by risk, and follow up care. Active surveillance, surgery (radical prostatectomy), external beam radiotherapy (EBRT), low dose rate (LDR) brachytherapy, cryosurgery, High Intensity Focused Ultrasound (HIFU), Androgen Deprivation Therapy (ADT), and systemic therapies are discussed as treatment options. Bone health is also reviewed. Outcomes of interest include survival and recurrence.
Developer organization: European Association for the Study of the Liver
This is a clinical practice guideline for the evaluation of liver disease severity and prognosis. The guideline considers the value of liver biopsy for fibrosis evaluation and compares it to other non-invasive tests. The guideline developers considered a number of different questions including: what are the currently available non-invasive tests; how do serum biomarkers perform for staging liver fibrosis; and what are the indications for non-invasive tests for staging liver disease in viral hepatitis.
Developer organization: Spanish Society of Pulmonology and Thoracic Surgery
This is a clinical practice guideline fore patients who have been diagnosed with or are at risk of developing non-small cell lung cancer (NSCLC). The guideline provides recommendations on disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis. Recommendations regarding clinical presentation are also presented, with specific topics such as imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function. The guideline also provides guidance on follow-up, when appropriate.
Developer organization: Brazilian Gastrointestinal Tumor Group
This is a clinical practice guideline for patients with biliary tract cancers, including gallbladder cancer, intrahepatic and extrahepatic cholangiocarcinoma, and cancer of the duodenal papilla. The guideline examines the diagnosis, staging, and treatment of these patients. Tests discussed for the diagnosis and staging include endoscopic retrograde cholangiopancreatography (ERCP), upper GI endoscopy (UGIE), endoscopic ultrasound (EUS), cholangioscopy, and laparoscopy. Surgical options are stratified by disease type, and both adjuvant treatment and systemic treatment for metastatic cancer of the biliary tract are also discussed.
This clinical practice guideline provides recommendations on the diagnosis and treatment of rectal cancer in adult patients. Imaging procedures for staging are discussed with comparisons made between ultrasound, MRI, and CT scan. Treatment options include neoadjuvant and adjuvant chemotherapy as well as rectal cancer surgery, specifically total mesorectal excision (TME). Surgical management of recurrent rectal adenocarcinoma is also discussed.
Developer organization: Japanese Breast Cancer Society
A clinical practice guideline for the pathological diagnosis of breast cancer in adults. The guideline examines diagnostic procedures based on routine clinical practice and treatment modalities. Outcomes of interest include diagnostic accuracy, concordance rates, and margin negativity.
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, primary urethral carcinoma. The guideline reviews diagnostic assessment, staging, and treatment. Treatment options include penile-preserving and urethral-sparing surgery, urethrectomy, radiotherapy, cisplatinum-based chemotherapy, chemoradiotherapy, transurethral resection (TUR), Bacille-Calmette-Guérin (BCG), and cystoprostatectomy with extended pelvic lymphadenectomy. Outcomes of interest include survival, sensitivity of diagnostic tests, local cure rate, local recurrence rate, and local tumour control rate.
Developer organization: Korean Liver Cancer Study Group (KLCSG)
This clinical practice guideline provides recommendations on prevention, diagnosis, and treatment of hepatocellular carcinoma. Treatment options are discussed including surgical resection, transplantation, local ablation, transarterial chemoembolization, external-beam radiation therapy, systemic therapies, preemptive antiviral therapy, and drug treatment for cancer pain. Assessment of tumour response and post-treatment follow-up are also reviewed.
Developer organization: Uveal Melanoma Guideline Development Group
A clinical practice guideline for the surveillance of patients following treatment for uveal melanoma and the use of new and systemic treatments. The guideline examines the effectiveness of new surveillance technologies, staging, and treatment including special consideration for patients with hepatic recurrence. Outcomes of interest include local tumour control, preservation of eye function, and progression free survival.
This is a clinical practice guideline addressing lymphoma in the adult population. The guideline focuses on the following areas: Diagnosis and Pathologic Classification, Staging, Treatment of Non-Hodgkin Lymphomas, Hodgkin Lymphoma, HDCT and hematopoietic stem cell transplantation for lymphoma, supportive care in the treatment of lymphoma, and follow-up care in the treatment of lymphoma. Additionally, it seeks to provide recommendations to the following questions: what are the diagnostic criteria for the most common lymphomas; what are the staging and re-staging procedures for Hodgkin and non-Hodgkin lymphomas; what are the recommended treatment and management options for Hodgkin and non-Hodgkin lymphomas; and what are the recommended follow-up procedures for patients with malignant Hodgkin and non-Hodgkin lymphoma.
Developer organization: American Society of Clinical Oncology
This is a guideline for the treatment and staging of small-cell lung cancer. The guideline examines treatment through chemotherapy, radiotherapy, and surgery with a focus on potential toxicity. Outcomes of interest include clarified duration of chemotherapy as a first-line treatment and increased use of PET scans for staging.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for small cell lung cancer and lung neuroendocrine tumours. Diagnosis, staging, prognostic factors, treatment and surveillance are reviewed. Treatment options include chemotherapy, with special topics of discussion including elderly patients and second-line and third-line therapies, radiotherapy (thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy), and surgery. Outcomes of interest include survival (disease free, overall, progression-free) and response rates, and treatment toxicity.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Hodgkin lymphoma. The guideline discusses the clinical management of patients with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), focusing exclusively on patients from post adolescence through the seventh decade of life who do not have serious intercurrent disease. Areas considered and discussed within the guideline include: staging and prognosis, the role of PET scans, treatment, principles of radiation therapy, and follow-up after completion of treatment.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations for the diagnosis and treatment of acute myeloid leukemia (AML). Induction therapy and post-remission (consolidation) therapy are reviewed with recommendations stratified by risk and age. Specific recommendations are provided for the management of acute promyelocytic leukemia (APL). The guideline also discusses therapy for relapse, evaluation and treatment of CNS leukemia, and supportive care.
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults age 18 years and older who are suspected of having or are newly diagnosed with bladder cancer or cancer of the urethra, or diagnosed with recurring bladder cancer or cancer of the urethra. The guideline provides recommendations on diagnosis, staging, and management of muscle-invasive, non-muscle invasive, locally advanced, and metastatic bladder cancers. Management of treatment side effects and follow-up care is also discussed. Outcomes of interest include survival (overall, disease-free), disease-related morbidity and mortality, treatment-related morbidity and mortality, psychological well-being, quality of life, admissions to hospital after diagnosis, adverse events, and cost-effectiveness.
Developer organization: European Association for Endoscopic Surgery
This is a clinical practice guideline for patients with early rectal cancer. The guideline provides recommendations on diagnosis, staging, and treatment. Local excision, rectal resection, and total mesorectal excision are discussed as surgical options, and laparoscopic and open approaches to abdominal surgery are compared. The use of neoadjuvant (chemo) radiation therapy is also discussed. Outcomes of interest include diagnostic accuracy, sensitivity, and specificity of diagnostic and staging procedures, local recurrence, survival (5-year, overall, disease free), distant metastases rate, morbidity, and quality of life.
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with epidermolysis bullosa. The guideline provides recommendations for the diagnosis, staging, and management of cutaneous squamous cell carcinoma (SCC) in these patients. Specific topics discussed include surveillance and diagnosis, tumour evaluation and staging, surgical treatment, nonsurgical treatment, the use of prosthetics, and end-of-life care.
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for the treatment of unknown primary head and neck cancer. An unknown or 'occult' primary is one where a primary tumour cannot be identified after appropriate investigation, in a patient with no prior history of head and neck cancer. The guideline provides recommendations on the initial workup of all patients with a neck mass, as well as recommendations for staging, management, and cases of recurrent disease.
This is a clinical practice guideline for the management of chronic myeloid leukemia (CML) in adult patients over 18 years of age. The 2015 update incorporates new evidence from research involving tyrosine kinase inhibitors for the treatment of CML. Guideline recommendations stem from the following three questions: what diagnostic and baseline investigations are recommended for adult patients with suspected or confirmed CML; what are the recommended treatment options for CML; and what are the criteria for monitoring response to treatment?
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup, staging, and treatment for both noninvasive and invasive breast cancer. Special considerations include phyllodes tumour, Paget's disease, breast cancer during pregnancy, and inflammatory breast cancer. Treatment recommendations for invasive cancer are stratified by tumour receptor status and stage. Fertility and birth control are also discussed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This clinical practice guideline discusses the use of combined endobronchial ultrasound (EBUS) and esophageal ultrasound (EUS-(B) for mediastinal nodal staging of lung cancer. The use of EBUS/EUS for the analysis of the primary lung tumour and the left adrenal gland is also discussed. Other topics of consideration include training issues. Outcomes of interest include sensitivity, specificity, diagnostic accuracy, complication rate, and positive and negative predictive values.
Developer organization: American Society for Gastrointestinal Endoscopy
This is a clinical practice guideline for the use of endoscopic approaches in the evaluation and treatment of ampullary adenomas. The guideline discusses evaluation of ampullary lesions before endoscopic therapy, the role of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) in assessment, and endoscopic resection. The role of EUS in management of duodenal adenomas is also examined. Adverse events and post-procedural care and surveillance are also addressed.
Developer organization: European Association of Urology
This is a clinical practice guideline on muscle-invasive and metastatic bladder cancer. This is an update to the European Association of Urology's 2000 guidelines on bladder cancer and provides recommendations related to staging, diagnostic evaluation, management, and follow-up. Issues addressed include: imaging, surgery, chemotherapy, radiotherapy, and recurrence.
Developer organization: Japanese Society of Gynecologic Oncology
A clinical practice guideline for treatment of uterine cervical cancer. The guideline examines updated evidence on primary treatments, treatment for recurrent cancers, and additional presentations, focusing primarily of lymphadenectomy and hysterectomy. Outcomes of interest include recurrence and fertility preservation.
Developer organization: Japanese Urological Association
This is a clinical practice guideline for patients with upper tract urothelial carcinoma (UTUC). The guideline provides recommendations on diagnosis and treatment, with discussions on surgery, radiotherapy, chemotherapy and other anticancer drug therapies. Topics include surgical techniques, the use of neoadjuvant versus adjuvant chemotherapy, postoperative follow-up care, the use of ureteroscopic kidney-sparing surgery, instillation of BCG or other anticancer drugs into the upper urinary tract, treatment of metastatic or recurrent UTUC, and use of radiotherapy alone as treatment. Epidemiology is also discussed.
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for patients diagnosed with or suspected of having small cell lung cancer. The guideline reviews screening, work-up, and treatment for limited stage and extensive stage cancer. Recommendations are also provided on follow up care.
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for the treatment of oral cavity cancer. The guideline addresses staging, pre-treatment investigations. management with recommendations given by cancer stage (stage I and II, advanced (T3) and very advanced (T4B) and by site (anterior tongue, buccal mucosa, floor of mouth, retromolar trigone, and hard palate and alveolar ridge). Follow up care is also reviewed.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the diagnosis, staging, and treatment of thyroid carcinoma. Recommendations are stratified by histologic type, namely papillary, follicular, Hürthle cell, medullary, and anaplastic. Primary treatment options and assessment and management after initial treatment is reviewed. Recurrent or persistent disease is also discussed.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adult patients with non-small cell lung cancer. The guideline provides updated recommendations around prevention and screening, evaluation and staging, treatment, and follow up. Areas of focus are discussed with recognition that much progress has been made in regards to screening, minimally invasive techniques for diagnosis and treatment, advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), and targeted therapies.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Non-Hodgkin's Lymphomas (NHL). The guideline focuses on recommendations for diagnostic workup, treatment, and surveillance strategies for the most common subtypes of NHL, in addition to a general discussion on the classification systems used in NHL and supportive care considerations. The most common NHL subtypes that are covered in the guideline are: Mature B-cell lymphomas, Mature T-cell and NK-cell lymphomas, Post Transplant Lymphoproliferative Disorders (PTLD), and Castleman's Disease.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for myelodysplastic syndromes (MDS). The guideline provides an update to recommendations on standard approaches to the diagnosis and treatment of MDS in adults. These recommendations are based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biological factors that may have prognostic significance in MDS.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for kidney cancer. The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on esophageal and esophagogastric junction (EGJ) cancers, including: a review of hereditary cancer predisposition syndromes associated with increased risk for esophageal and EGJ cancers, staging and pathology, imaging, and treatment including surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies. Surveillance, management of metastatic, or recurrent cancer, and best supportive care are also discussed. Special topics of interest include treatment and surveillance options for patients with Barrett's esophagus, and suggested strategies to help alleviate the current problems associated with leucovorin shortage.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.
Developer organization: American Society for Gastrointestinal Endoscopy
This clinical practice guideline discusses the use of endoscopy in patients with malignant and premalignant conditions of the stomach including gastric polyps, gastric intestinal metaplasia (GIM), pernicious anemia, gastric carcinoid tumours, adenocarcinoma, mucosa-associated lymphoid tissue (MALT) lymphoma, and GI stromal tumours (GISTs). Surveillance endoscopy, staging ultrasound, biopsy, polypectomy, resection (surgical and endoscopic), and open gastrojejunostomy are discussed. Outcomes of interest include risk factors for dysplasia and gastric cancer, as well as survival rate, accuracy of staging techniques, and treatment complication rate.
Developer organization: European Neuroendocrine Tumor Society
A clinical practice guideline for patients with pulmonary neuroendocrine (carcinoid) tumours, including typical and atypical presentations. The guideline examines diagnosis and staging, primarily through pathology and contract CT, and treatment focusing on surgical management.
Developer organization: American College of Radiology
A clinical practice guideline for renal cell carcinoma staging. The guideline examines staging through multiple imaging modalities, including CT, MRI, PET, bone scans, chest radiography, ultrasound, and arteriography. Outcomes of interest include diagnostic accuracy, reduced cost, and detection of metastasis.
This is a clinical practice guideline for patients with Barrett's esophagus (BE) without dysplasia and BE with dysplasia and/or early esophageal adenocarcinoma (EAC). Topics of discussion include: endoscopic and histological definitions of BE and early EAC; prevalence, incidence, natural history, and risk factors for BE and early EAC; and management of BE and early EAC, including modification of lifestyle factors, screening, surveillance, and medical, endoscopic, and surgical interventions.
Developer organization: American College of Radiology
This is a clinical practice guideline for adults with nasopharyngeal carcinoma. Clinical presentation and evaluation is reviewed, and treatment recommendations are provided for Stage I, II, and III or IV disease. Treatment of recurrent or metastatic disease is also discussed. Outcomes of interest include toxicity from treatment, overall survival, progression-free survival, and distant control.
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the staging and treatment of squamous cell carcinoma. The guideline examines treatment options, primarily surgical excision, and provides guidelines for immunocompromised and high-risk patients. Outcomes of interest include improved tissue sparing through Mohs micrographic surgery, and improved understandings of surgical margins. This guideline is Chapter 5 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guide for the staging and treatment of basal cell carcinoma. The guideline examines numerous treatment options, including cryosurgery, topical, and photodynamic approaches. Outcomes of interest include reduced recurrence rates with surgical excision and Mohs micrographic surgery. This guideline is Chapter 4 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.
This is a clinical practice guideline for adults over the age of 18 years with unresectable stage III and stage IV cutaneous melanoma, without involvement of the central nervous system (CNS). The guideline reviews the use of BRAF biomarker testing, and provides recommendations for first- and second-line systemic therapy options. BRAF Inhibitors, MEK inhibitors, immune checkpoint Inhibitors, other biological agents (e.g. imatinib and bevacizumab), and chemotherapy agents are reviewed.
This is a clinical practice guideline for adults over the age of 18 years with Merkel cell carcinoma of the skin. The guideline provides recommendations on staging and work-up, treatment options including surgery, radiation, and chemotherapy, and follow-up care. The guideline also provides recommendations on management of recurrences, and reviews sentinel lymph node biopsy protocol.
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with pancreatic cysts. The guideline evaluates the evidence for diagnosing and managing pancreatic cysts. Important aspects discussed in the guideline include the taking of a detailed patient history, the use of imaging, and surgery. Outcomes of interest include the prevention of mortality from cystadenocarcinoma, the appropriateness of surgical intervention, and the progression of malignancy.
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular cancer. The guideline provides recommendations on clinical presentation, diagnostic workup, risk assessment, and treatment. Management options are stratified by stage and cancer type (seminoma or nonseminoma). Second-line therapy for metastatic germ cell tumours is reviewed with recommendations provided for palliative therapy and treatment of brain metastases.
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumours, and osteosarcoma. Surveillance and relapse are also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.
A clinical practice guideline for the management of adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline examines treatment, primarily through surgery and radiotherapy, staging, and follow-up. Outcomes of interest include improved survival benefits through chemoradiotherapy and improved outcomes thought the addition of ifosamide to recommended chemotherapies.
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients with locally advanced stage III non-small-cell lung cancer (NSCLC). The guideline reviews heterogeneity in disease and provides recommendations on sub-staging, diagnostic work-up, assessment of relevant comorbidities, and treatment including chemotherapy, radiation, multi-modality therapies, surgical management, and targeted agents. Follow-up is also discussed. Outcomes of interest include mortality, survival (5 year, long-term), remission rates, and toxicity.
This clinical practice guideline addresses care of adult patients with differentiated thyroid cancer, specifically within Nova Scotia. The guideline provides recommendations on pre-surgical evaluation of thyroid nodules, surgical treatment and complications, pathology reporting, grading and tumour staging (TNM), risk prognostic systems, and post-surgical radioactive iodine (RAI) therapy. Protocols for lab and diagnostic follow-up, management of local and regional recurrences, early and long-term follow-up, and supportive and palliative care management are also addressed.
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with invasive cancer of the cervix. The guideline addresses staging techniques using imaging. This includes a review of the use of radiographs, excretory urography, transabdominal ultrasound (TRUS), computed tomography (CT), magnetic resonance imaging (MRI), lymphangiography and lymphoscintigraphy, positron emission tomography (PET) and PET/computed tomography, and nuclear medicine bone scan. Trachelectomy assessment is also discussed.
This is a clinical practice guideline for adult patients with adenocarcinoma of the pancreas. The guideline discusses diagnostic workup, treatment options for potentially curable adenocarcinoma of the pancreas, and management of unresectable adenocarcinoma of the pancreas including locally advanced and metastatic disease. Surgical and first and second line systemic treatment options are discussed. Toxicity of systemic therapy regimes is also reviewed.
This is a clinical practice guideline for adult patients over the age of 18 years with acute myeloid leukemia. The guideline reviews diagnosis, classification, ancillary tests, response criteria, prognosis/risk stratification, risk groups as per cytogenetic or molecular status, and management options. Treatments reviewed include chemotherapy, hematopoietic stem cell transplantation, and palliation. Follow up care is also discussed.
Developer organization: Belgian Health Care Knowledge Centre
This clinical practice guideline discusses genetic testing for patients diagnosed with or suspected of having hereditary endocrine cancer syndromes, specifically multiple endocrine neoplasia type 2 (MEN2), multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL) syndrome, and paraganglioma and phaeochromocytoma. Indications for genetic testing of relatives of patients is also reviewed. Genetic testing for Succinate Dehydrogenase B, C and D (SDHB, SDHC, SDHD), menin, VHL and RET mutations are discussed. Outcomes of interest include diagnostic accuracy, health outcomes, and psychosocial outcomes.
Developer organization: American College of Gastroenterology
This is a clinical practice guideline for patients diagnosed with or at risk of hereditary gastrointestinal cancer syndromes including lynch syndrome, familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP), MUTYH-associated polyposis (MAP), Peutz–Jeghers syndrome, juvenile polyposis syndrome, Cowden syndrome, serrated (hyperplastic) polyposis syndrome, hereditary pancreatic cancer, and hereditary gastric cancer. The guideline reviews initial assessment, genetic testing for a germline mutation when indicated, pre- and post-test genetic counselling, and management of patients who meet clinical criteria for a syndrome as well as those with identified pathogenic germline mutations. Outcomes of interest include cancer risk, quality of life, and survival benefit from surveillance.
Developer organization: International Liver Cancer Association (ILCA)
This is a clinical practice guideline for patients diagnosed with or suspected of having intrahepatic cholangiocarcinoma (iCCA). The guideline discusses iCCA incidence, risk factors, and molecular pathogenesis, and provides recommendations on diagnostic assessment, staging, and management. Treatment options including surgery, liver transplantation, loco-regional therapy, and systemic therapy are discussed. Outcomes of interest include survival (recurrence-free, median, three-year, five-year), quality of life, and toxicity.
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for patients with oral cavity cancers. The guideline examines diagnosis, treatment, and follow-up with a focus on radiotherapy and appropriate imaging techniques. Outcomes of interest include improved supportive care through nutritional therapy and improved follow-up timing.
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for female patients aged 19 and older. The guideline provides recommendations on the screening, diagnosis, treatment, and follow-up care of endometrial cancer. Prevention and risk reduction strategies are also discussed.
Developer organization: American Brachytherapy Society
A clinical practice guideline for the use of plaque brachytherapy in patients with choroidal melanoma and retinoblastoma. The guideline examines appropriate staging criteria, treatment planning, and alternative surgical and radiation therapy techniques. Outcomes of interest include improved visual acuity and local control.
Developer organization: British Thyroid Association
A clinical practice guideline for the management of patients with differentiated and medullary thyroid cancer. The guideline examines the management of thyroid cancer from diagnosis to follow-up, with specific focus on radioiodine remnant ablation and appropriate post-treatment follow-up. Outcomes of influence include improved outcomes in total thyroidectomy and improved personalised decision making.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult and pediatric hepatocellular cancer patients. The guideline examines assessment and treatment for both curative and non-curative therapies. Outcomes of interest include clarified follow-up timing and early involvement of supportive care.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with biliary tract and gall bladder cancers. The guidelines examines assessment and treatment based on disease staging or re-staging, primarily thought chemotherapy or surgery. Outcomes of interest include improved nutritional supplementation and reduced need for follow-up imaging.
A clinical practice guideline for the management of esophageal cancer. The guideline examines pre-treatment workup, staging, and treatment, primarily through surgical methods. Outcomes of interest include more complete esophageal dissection and clarified options for palliative care.
This is a clinical practice guideline for male patients who have undergone radical prostatectomy for clinically localized prostate cancer and who have been found to have either positive surgical resection margins (R1), tumour extension beyond the prostatic capsule (pT3a), seminal vesicle invasion (pT3b), or more than one of these features. The guideline provides recommendations on the use of adjuvant radiotherapy following radical prostatectomy. Outcomes of interest include survival (prostate cancer-specific, metastasis-free, biochemical progression-free, and locoregional recurrence-free), time to initiation of androgen deprivation therapy, toxicity (acute and late), and quality of life.
Developer organization: European Association of Urology
A clinical practice guideline for the management of muscle-invasive and metastatic bladder cancer. The guideline examines diagnosis and staging with specific focus on imaging recommendations, including MRI and CT. Treatment options, including radical chemotherapy and surgery are also discussed based on imaging results. Outcomes of interest include improved treatment selection, specifically in cases where previous treatments have failed.
This clinical practice guideline reviews the use of sentinel node biopsy (SLNB) as a diagnostic tool for adult patients with malignant melanoma. The guideline reviews indications and contraindications of SLNB, pathological examination of the sentinel nodes, and indications for therapeutic node dissection and recommended extent of dissection. The use of ultrasound-guided fine-needle aspiration is also discussed. Outcomes of interest include test sensitivity, specificity, and positive and negative predictive value, as well as rate of nodal recurrence and survival.
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline for patients with suspected or confirmed multiple myeloma. Diagnostic procedures are recommended and treatment options outlined, including chemotherapy, induction therapy, high-dose therapy and autologous stem cell transplantation (ASCT), and allogeneic stem cell transplantation (AlloSCT). Recommendations are also provided for maintenance therapy and the treatment of medical conditions common in patients with myeloma. Outcomes of interest include treatment response rate, survival, toxicity, quality of life, and treatment-related mortality.
This is a clinical practice guideline for the diagnosis and treatment of cancer and associated malignancies in adult patients with HIV. The guideline examines the most common HIV associated cancers, Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer, as well as a number of other cancers with higher risk profiles in HIV patients. Outcomes of interest include improved treatment options in consideration of HAART and increased prophylactic options in low-risk patients, specifically with regards to lifestyle changes and vaccinations.
This is a clinical practice guideline for patients with rectal cancer who are newly diagnosed. The guideline provides recommendations on investigations to assess for metastases and synchronous lesions, imaging for local staging, optimal MRI protocol and criteria for local staging, optimal MRI criteria to select patients for neoadjuvant therapy, the role of multidisciplinary cancer conferences and the role of restaging MRI after neoadjuvant therapy.
Developer organization: Society of Gynecologic Oncology
This is a clinical practice guideline for women with endometrial carcinoma. The guideline reviews treatment options including: adjuvant therapy including radiation, vaginal brachytherapy, and chemotherapy; and therapy for advanced disease. Treatment for synchronous endometrial and ovarian cancer, fertility-sparing treatment, post-treatment patient surveillance, and the role of hormone replacement therapy in the development of endometrial carcinoma are also discussed. Outcomes of interest include survival (overall, 5-year, disease-specific), locoregional recurrence rate, survival rate after recurrence, and toxicity.
This is a clinical practice guideline for patients over the age of 18 years with primary germ cell tumours (GCTs) of the central nervous system. The guideline discusses staging and diagnosis, treatment, and follow-up care. Recommendations for treatment options are provided for germinoma and nongerminomatous GCT, and are stratified by whether disease is localized or metastatic. Additional recommendations are made for recurrent treatment, again stratified by histology.
Developer organization: American Brain Tumor Association
A clinical practice guideline for adult patients with brain tumours, specifically focusing on nursing activities. The guideline examines management from diagnosis to survivorship or end-of-life care, with specific focus on symptom management and communication with patients and family. Outcomes of interest include improved patient education and supportive communication..
Developer organization: Joint Guidelines Committee of the Congress of Neurological Surgeons and American Association of Neurological Surgeons
This is a clinical practice guideline for adult patients with progressive glioblastoma. The guideline reviews diagnostic criteria and provides recommendations on techniques and ancillary studies that are most useful in separating malignant progression from treatment effect. Outcomes of interest include sensitivity, specificity, positive and negative predictive value, accuracy, and likelihood ratio of a positive and negative result.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with pancreatic cancer. The guideline examines assessment and treatment, primarily through radical resections including Whipple procedures. Outcomes of interest include reduced chemotherapy toxicity with gemcitabine and improved follow-up procedures.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for gastric and gastro-esophageal junction cancer patients. The guidelines examines assessment by a multidisciplinary team, and treatment options including gastrectomy and endomucosal resection. Outcomes of interest include increased survival through combination therapy and potential benefit from biomarker targeted therapies.
This is a clinical practice guideline for patients with anal canal cancer. The guideline provides recommendations for the pre-treatment evaluation, staging, and treatment options. Recommendations include a consideration of the appropriateness of x-ray, CT, and MRI; the American Joint Commission on Cancer pathological staging system; as well as resection, chemotherapy and radiotherapy.
Developer organization: Brazilian Society of Endocrinology and Metabolism
This is a clinical practice guideline for individuals with or suspected of having Medullary thyroid carcinoma (MTC). The guideline provides recommendations on diagnosis, surgical treatment, and follow-up care. The use of chemotherapy and/or radiotherapy in the management of individuals with metastatic MTC is also discussed. The appropriate use of RET proto-oncogene molecular testing during diagnostic assessment is discussed, and the potential value in the use of tyrosine-kinase inhibitors as a treatment option is reviewed. Outcomes of interest include survival rate (median, overall, 10-year, progression-free), sensitivity and specificity of diagnostic tests, cure rate, rate of remission, and recurrence rate.
This guideline set provides recommendations on the management of head and neck cancers including oral and dental care. Topics of discussion include predisposing factors, prevention, screening, early detection, diagnosis and staging, management, and follow-up. Additionally, oral care through chemotherapy, radiation therapy, and bone marrow transplantation are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on the management of gynecologic cancers including gynecological sarcomas and cancers of the ovary (epithelial and non-epithelial carcinomas), endometrium, uterine cervix, vulva, fallopian tube, gestational trophoblastic neoplasia, and vagina. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, prevention and screening are discussed for ovarian, endometrial, and cervical cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This is a clinical practice guideline for adults suspected of having or diagnosed with adult onset sarcoma. The guideline provides recommendations on diagnosis and staging, treatment, and follow-up care. Chemotherapy, radiotherapy, and surgery are discussed as treatment options. Outcomes of interest include local recurrence, survival (overall, long term), and quality of life.
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for adults diagnosed with or suspected of having soft tissue or visceral sarcoma. The guideline discusses diagnosis, staging and risk assessment, and treatment stratified by whether disease type is localized or advanced. Follow-up care is also reviewed. Treatment options for patients with special presentations and entities is also discussed, including patients with retroperitoneal sarcomas, uterine sarcomas, desmoid-type fibromatosis, and breast sarcomas.
This clinical practice guideline provides recommendations on pancreatic cancer management including pre-treatment evaluation, surgical pathology report requirements, staging classifications, assessment of resectability, and treatment. Pancreatico-duodenectomy, radiotherapy, chemoradiotherapy, and chemotherapy are discussed as treatment options depending on resectability. Management of metastatic pancreatic cancer and locally recurrent disease are included in this review.
This is a clinical practice guideline for the pre-treatment evaluation, staging, and treatment of colorectal cancer. Topics addressed in the guideline include an overview of surgical pathology report requirements; as well as treatment options for clinically localized resectable colon cancer, clinically localized resectable rectal cancer, and locally advanced unresectable or metastatic colon or rectal cancer.
A clinical practice guideline for patients with esophagogastric junction tumour. The guideline examines staging, pre-treatment evaluation, treatment through surgery and adjuvant therapy, and basic follow-up. Important aspects include surgical pathology report requirements and post-operative management.
Developer organization: International Study Group on Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for patients with resectable pancreatic ductal adenocarcinoma. The guideline provides recommendations on pancreatoduodenectomy, with comparisons made to extended versus standard lymphadenectomy during surgery. Primary outcome of interest is survival benefit.
Developer organization: International Study Group of Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for pancreatic cancer. The guideline examines treatment options for borderline resectable pancreatic ductal adenocarcinoma (BRPC). Topics explored in this guideline include: operative exploration, resection in the case of involvement of the mesentericoportal venous axis, and regimens of neoadjuvant therapy.
This guideline set provides recommendations on required reports for referrals for: breast, gastrointestinal (esophagus, stomach, colon-rectum, anus, pancreas, liver, biliary tract/gall bladder), genitourinary (testis, prostate, bladder), gynecology (endometrium, cervix, ovary, vulva & vagina), head and neck (parotid & submandibular gland, thyroid, mouth, palate, nasopharynx, oropharynx, hypopharynx, nose & antrum, ear), lung, lymphoma and leukemia, melanoma, musculoskeletal and sarcoma, neuro-oncology, primary unknown, and skin (basal cell & squamous cell carcinomas, mycosis fungoides – Sezary syndrome). The guideline provides recommendations on pathology reports, operative reports, laboratory reports, and imaging reports. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on the management of skin cancers including melanoma and non-melanoma. Topics of discussion include potential precursors, surveillance and early detection, diagnosis and staging, and management. Additionally, referral information and management policies are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on the management of musculoskeletal cancers including bone cancer and soft tissue sarcoma. Topics of discussion include prevention, diagnosis and staging, management, and follow-up. Additionally, diagnostic pathology, and treatment through chemotherapy, radiotherapy, and surgery are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on the management of lung cancers including mesothelioma and thymomas. Topics of discussion include prevention, early detection, diagnosis and staging, and management. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This is a clinical practice guideline for breast cancer. The guideline examines demographics and risk factors, prevention, screening and early detection, diagnosis, staging, management, and follow-up. Other important aspects explored in the guideline include: upper extremity rehab after axillary dissection, exercise for cardiovascular fitness, as well as benefits, risks, and costs. Please note that the sub-sections within this guideline were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline was accessed online.
This is a clinical practice guideline for the early detection of common cancers in adolescents and young adults aged between 15 and 24 years of age. The cancers covered include leukemia, lymphoma, brain tumours, soft tissue sarcoma, testicular cancer, thyroid cancer, and melanoma. The guideline discusses common signs and symptoms and provides recommendations on clinical assessment and referral. "Youth-friendly" communication between practitioner and patient is also discussed, and links for patient and practitioner resources are provided.
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients diagnosed with or at risk of having anal cancer. The guideline outlines screening and prevention, diagnostic assessment and staging, treatment, and follow-up and surveillance. Special topics of interest include treatment of the elderly and personalized medicine. Management of advanced/metastatic disease is also discussed. Outcomes of interest include survival, recurrence rates and quality of life.
This is a clinical practice guideline for adult patients with hepatocellular carcinoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Treatment options including resection, liver transplantation, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), transarterial chemo-embolization (TACE), transarterial radioembolization (TARE), sorafenib, and stereotactic body radiotherapy (SBRT) are reviewed.
This is a clinical practice guideline for patients over 18 years of age with pancreatic cancer. The guideline reviews diagnostic work-up, staging, and treatment options for both potentially curable and unresectable pancreatic cancer. Comparisons are made between FOLFIRINOX and gemcitabine chemotherapy regimes. Outcomes of interest include survival, adverse events, and response rate.
This is a guideline for adjuvant systematic therapy for early stage (lymph node negative and lymph node positive) breast cancer. The guideline discusses risk categories for lymph node negative breast cancer, provides treatment recommendations for lymph node negative breast cancer, and explores chemotherapy options for lymph node negative breast cancer. Other areas of interest include: treatment recommendations for lymph node positive breast cancer, chemotherapy options for lymph node positive breast cancer, and adjuvant hormonal therapy for hormone receptor positive disease only.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with esophageal cancer and gastro-esophageal junction cancer. The guideline examines diagnostic assessment and proposed treatment based on cancer staging, with a focus on chemoradiation and surgical therapies. Outcomes of interest include improved recommendations for patients with good and poor performance.
This is a clinical practice guideline for patients diagnosed with borderline resectable or locally advanced pancreatic cancer. The guideline reviews pre-treatment staging, therapeutic options including biliary decompression and neoadjuvant therapy, chemotherapy with and without gemcitabine, chemoradiation therapy (CRT), induction chemotherapy and CRT, and radiological re-evaluation. Outcomes of interest include survival (median, overall, progression-free), treatment toxicity, adverse events, and surgical resectability rates.
This clinical practice guideline provides recommendations in relation to sentinel lymph node biopsy (SLNB) in vulvar cancer. The guideline seeks to determine whether SLNB can safely and effectively identify women with node-negative, early-stage vulvar cancer and can be used as an alternative to inguinofemoral lymph node dissection (IFLD). Additionally, the guideline provides guidance with respect to the appropriate techniques and procedures in SLNB for women with early-stage vulvar cancer. These include: the selection of appropriate patients; determining the appropriate technique, and management of patients with positive sentinel lymph nodes.
Developer organization: European Association of Urology
A clinical practice guideline for the management of renal cell carcinoma. The guideline examines the diagnosis, staging, treatment, and follow-up of renal cell carcinoma, including updates on histology and localized disease treatment through venous thrombus. Outcomes of interest include improved management through nephron-sparing surgery and improved surveillance for small renal masses.
Developer organization: European Association of Urology
A clinical practice guideline for the management of penile cancers in adult male patients, focusing primarily on penile squamous cell carcinoma. The guideline examines the full continuum of cancer care for penile cancer patients, and provides a variety of treatment options based on staging and diagnosis. Outcomes of interest include improved functional and cosmetic treatment and reduced nodal recurrence.
A clinical practice guideline for the management of patients with small cell and non-small cell lung cancer. The guideline examines the continuum of care for lung cancer, including the importance of smoking cessation, staging investigations, surgery as a curative option, radiotherapy recommendations, and palliative care considerations. Outcomes of interest include survival benefits with non-surgical management, reduced side effects in second line therapies, and increased staging specificity.
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for men with suspected or diagnosed localised, locally advanced, or metastatic prostate cancer. The guideline examines diagnosis and staging, primarily through PSA testing and biopsy, as well as timelines for active surveillance options. The guideline also examines multiple treatment options based on cancer staging, including hormone therapy, radiotherapy, and radical surgical options. Outcomes of interest include increased prediction of outcomes, overall survival, and reduced risk of bone density loss.
This is a clinical practice guideline for patients with apparent early stage endometrial cancer at the time of diagnosis, that may have low or high risk features. The guideline examines pre-operative investigations, surgery techniques, and adjuvant treatment including radiotherapy and chemotherapy, with recommendations taking risk into consideration. The use of multidisciplinary team management is also discussed. Outcomes of interest include treatment risks, complications, and survival rates. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of July 11, 2014
Developer organization: American College of Radiology
This is a clinical practice guideline for the management of patients with diffuse large B-cell lymphoma (DLBCL). The guideline provides recommendations for diagnosis, staging, and treatment, and the appropriateness of different techniques is examined for different clinical situations. Outcomes of interest include overall survival, event-free survival, progression-free survival, failure-free survival, adverse events, and toxicity.
Developer organization: European Association of Urology
A clinical practice guideline for prostate cancer patients, particularly older men. The guideline examines diagnosis, staging, treatment and follow up, primarily for locally advanced and metastatic cancers. Outcomes of interest include improved functional outcomes and improvements in deferred treatment.
Developer organization: British Committee for Standards in Haematology
This clinical practice guideline reviews pre-treatment evaluation, management, follow-up, late effects, and survivorship of patients with classical Hodgkin lymphoma (HL). The guideline reviews management of early and advanced stage HL, as well as HL in pregnancy and in elderly patients. Chemotherapy and radiotherapy are discussed as treatment options, and PET/CT imaging is reviewed as a pre- and post-treatment assessment tool. Outcomes of interest include therapy related efficacy and toxicity, predictive value of assessment tools, survival, morbidity, and mortality.
This guideline set provides recommendations on the management of hematologic cancers including amyloidosis, chronic leukemia, Hodgkin's lymphoma and other forms of lymphoma, monoclonal gammopathy of unknown significance, multiple myeloma, and solitary plasmacytoma. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, biopsy procedures, protein studies, and immunizations for this population are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on gastrointestinal cancer, with sub-sections discussing the following tumour sites: anus, bile duct, colon, esophageal and esophagogastric junction, gallbladder, liver, neuroendocrine tumours, lymphoma, gastro-intestinal stromal tumours (GIST), pancreas, rectum, small bowel, and stomach. Important aspects discussed in the guideline include: screening, diagnostic and staging, surgical therapy, staging, follow up and surveillance, and considers different treatment options. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
Developer organization: Society of Gynecologic Oncology
This is a clinical practice guideline for patients diagnosed with or suspected of having endometrial cancer. The guideline reviews diagnostic evaluation, staging, and surgical management. The use and value of various surgical approaches including hysterectomy, lymphadenectomy, and cytoreductive surgery are discussed. Outcomes of interest include sensitivity, specificity, and positive predictive value of staging procedures, postoperative morbidity, and survival rates.
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for adult patients diagnosed with or suspected of having colon cancer. The guideline provides recommendations on diagnostic assessment and staging, pathology, treatment, and follow-up care. The use of KRAS mutational analysis and BRAF are reviewed, and N-RAS and MSI are discussed as predictors of treatment effectiveness. Comparisons are made between chemotherapy regimes, surgical techniques, and recovery programs. Outcomes of interest include sensitivity and specificity of diagnostic tests, survival (progression-free, overall), surgical outcomes (mortality, complications, readmissions, hospital stay, peri-procedural morality), and quality of life.
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for female patients aged 19 and older. The guideline provides recommendations on screening, diagnosis, treatment, and follow-up care of ovarian, fallopian tube, and primary peritoneal cancers. Prevention and risk reduction strategies are also reviewed.
This is a clinical practice guideline for patients with a pathological confirmed diagnosis of breast cancer. The guideline reviews diagnostic assessment, staging, and neoadjuvant treatment regimes depending on whether breast cancer is operable or inoperable. The guideline also discusses challenges involved with neoadjuvant therapy.
Developer organization: European Society of Endocrine Surgeons (ESES)
This is a clinical practice guideline for minimally invasive thyroid carcinoma (MIFTC). The guideline considers recommendations in the management of patients with MIFTC. Topics of consideration include: MIFTC definition, specimen processing, characteristics, diagnosis, prognoses, and therapy. Also of interest in the guideline is the distinction between MIFTC and widely invasive follicular thyroid carcinoma (WIFTC).
This guideline set provides recommendations on the management of metastatic cancer of unknown primary site including primarily adenocarcinomas and undifferentiated carcinomas. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, diagnostic pathology and special patient clusters are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on the management of neurological cancers including five primary subgroups: astrocytoma, oligodendroglioma, ependymoma, meningioma, and pituitary adenoma. Topics of discussion include prevention, diagnosis and staging, management, and follow-up. Additionally, the use of corticosteroids and anticonvulsants are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This guideline set provides recommendations on genitourinary cancer, with sub-sections on: prostate, bladder, kidney, testis, penis, scrotum, renal pelvis and ureter, and female urethra. Important aspects discussed in the guideline include: predisposing factors and prevention, screening and early detection, diagnosis, staging, and management. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.
This clinical practice guideline discusses cervical cancer control including: cervical cancer prevention and control programmes; community mobilization, education and counselling; HPV vaccination; screening and treatment of cervical pre-cancer; diagnosis and treatment of invasive cervical cancer; and palliative care. Treatment options for special populations including women who are pregnant and women living with HIV are also reviewed.
Developer organization: European School of Oncology
This is a clinical practice guideline for the treatment of patients with advanced breast cancer (ABC). Treatment options are discussed for inoperable locally advanced breast cancer (LABC), both inflammatory and non-inflammatory; and metastatic breast cancer (MBC), with recommendations specific to site of metastasis. Treatment recommendations are further stratified by cancer subtype (tumour status) and by specific populations including patients with BRCA-associated triple-negative or endocrine-resistant MBC and male patients with ABC.
This is a clinical practice guideline for patients over 18 years of age with primary invasive SCC cutaneous squamous cell carcinoma. The guideline reviews risk factors, staging, therapeutic interventions, and follow-up care. Outcomes of interest include prognostic factors, survival (five-year overall and recurrence free), local control, recurrence rate (regional and distant), nodal metastases, effectiveness of treatment, and adverse events.
This is a clinical practice guideline for patients with malignant uveal melanoma. The guideline reviews diagnosis and work-up, primary management, adjuvant therapy, management of patients with metastatic disease, and management of high risk patients. Follow-up care is also discussed. Outcomes of interest include efficacy of treatments and imaging modalities.
A clinical practice guideline for the treatment of newly diagnosed and recurrent or relapsed medulloblastoma in adult patients. The guideline examines MRI workup, surgery with maximal safe resection, and management of localized and non-localized recurrence. Outcomes of interest include improved long-term survival rates with maximal excision and improved local control with postoperative radiotherapy.
Developer organization: British Committee for Standards in Haematology
A clinical practice guideline for patients with, or being screened for, Waldenström macroglobulinaemia. The guideline examines management, including consistent monitoring of immunoglobulin and biological therapy with rituximab-containing regimens. Outcomes of interest increased treatment uniformity and solidified indications for introduction of treatment.
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for female patients aged 9 and above. The guideline provides recommendations on screening, diagnosis, treatment, and follow-up care of human papillomavirus (HPV) related cancers including cervical, vaginal, and vulvar. Special topics of interest include an overview of HPV vaccines and a discussion on controversies in care, including screening intervals and age to stop screening.
This is a clinical practice guideline for adult patients over 18 years of age with possible chronic lymphocytic leukemia. The guideline reviews the management of chronic lymphocytic leukemia, including diagnosis and prognosis, first-line and second-line treatment options, and follow-up and supportive care. Outcomes of interest include survival (overall and progression-free), toxicity, overall response, and quality of life.
This is a clinical practice guideline for the diagnosis and treatment of pancreatic cancer. Diagnosis, surgery, adjuvant therapy, radiation therapy, chemotherapy, and stent therapy are discussed. Outcomes of interest include survival and treatment efficacy.
Developer organization: Society for Immunotherapy of Cancer
A clinical practice guideline for the treatment of cutaneous melanoma patients with tumour immunotherapy. The guideline examines the clinical application of immunotherapy with interferon‐α2b, pegylated‐interferon‐α2b, interleukin‐2 (IL‐2) and ipilimumab for high-risk, advanced-stage cancer. Outcomes of interest include decreasing the adverse effects of depression and improved therapeutic strategies with immunotherapy and standard radiation.
Developer organization: European Study Group on Cystic Tumours of the Pancreas
A clinical practice guideline for patients with cystic tumours of the pancreas. The guideline examines the diagnosis and management of pancreatic tumours, including assessment of biopsy and surgical assessment. Outcomes of interest include improved diagnostic imaging and improved follow-up.
This is a guideline for patients who have been diagnosed with cancer of the breast and meet the selection criteria for sentinel lymph node biopsy (SLNB). The guideline reviews SLNB versus axillary lymph node dissection (ALND) and provides recommendations on patient selection, optimal technique for the use of SLNB, and surgical training. Recommendations are provided for managing challenging situations including ALND when SN is positive, intraoperative assessment of SN(s), ductal carcinoma in situ (DCIS), and multiple sentinel nodes.
This clinical practice guideline provides recommendations on optimal staging investigations for patients with newly diagnosed primary cancer of the rectum. Diagnostic procedures are reviewed including digital rectal examination (DRE), rigid proctoscopy, total colonoscopy, Intraluminal Endoscopic Ultrasound (EUS), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) , and Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/CT Scanning. Outcomes of interest include test sensitivity and specificity.
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for women over 19 years of age who have biopsy-proven breast cancer. The guideline provides recommendations on specialist referral, treatment, and follow-up care including surveillance for breast cancer recurrence or new cancer, monitoring and treating complications and/or treatment side effects, and providing patient support.
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients diagnosed with or suspected of having gestational trophoblastic disease (GTD). The guideline reviews diagnosis, staging, management of disease, and follow-up care. Treatment options for gestational trophoblastic tumours, placental site trophoblastic tumour/epithelioid trophoblastic tumours, and drug-resistant disease are reviewed. Outcomes of interest include survival, remission rate, toxicity, prognostic factors, and disease relapse.
Developer organization: American Society for Colposcopy and Cervical Pathology
A clinical practice guideline for patients with, or suspected of having, HPV associated lesions of the lower anogenital tract. The guideline examines appropriate terminology for cancers of the anogenital region and provides a diagnostic and histopathologic nomenclature system for use in clinical settings. Outcomes of interest include clarified margins for squamous cells and lesions in terms of both regional definition and staging.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with endometrial cancer. The guideline examines diagnosis and treatment options for pre- and post-menopausal women, with specific focus on the surgical extent of treatment. Outcomes of interest include improved recommendations for laparoscopy and improved accuracy of lymphadenectomy for staging.
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline for patients with mature T-cell and natural killer (NK)-cell neoplasms (excluding cutaneous T-cell lymphoma). Diagnostic assessment, staging, and treatment options are reviewed. The guideline also discusses antimicrobial prophylaxis and central nervous system (CNS) prophylaxis during therapy. Outcomes of interest include survival, response rate, rate of remission, disease progression, predictive value of diagnostic testing, and treatment related toxicity.
A clinical practice guideline for adult patients with upper tract urothelial carcinoma. The guideline examines staging, treatment, and follow-up, focusing on laboratory work-ups and primary therapy. Outcomes of interest include reduction of tumour recurrence through open bladder cuff excision and higher response rates with neoadjuvant chemotherapy.
This is a clinical practice guideline for patients over 18 years of age with squamous cell carcinoma of the vulva. The guideline reviews pre-operative investigations, primary treatment, adjuvant treatment, and follow-up and surveillance, with general and stage-specific recommendations provided. Outcomes of interest include cancer-related death rate, survival (overall and disease-free), progression-free interval, local control, and recurrence rate.
This is a clinical practice guideline for patients with muscle invasive bladder cancer (i.e., stages T2a/b, T3a/b, T4a and N0-X, M0). The guideline reviews evaluation and staging, treatment, and follow-up care according to stage. Outcomes of interest include survival, recurrence rate, bladder preservation rate, rate of metastasis, and presence of residual disease.
Developer organization: European Association of Urology
A clinical practice guideline for non-muscle-invasive bladder cancer patients. The guideline examines diagnosis and treatment, with specific reference to intravesical treatment techniques. Outcomes of interest include improved Bacillus Calmette-Guérin (BCG) immunotherapy protocols and improved early detection.
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for patients with small cell lung cancer (SCLC). Diagnostic and staging procedures are reviewed and recommendations are provided for treatment depending on stage. Treatment options include platinum-based chemotherapy with or without concurrent accelerated hyperfractionated radiation therapy, prophylactic cranial irradiation (PCI), consolidative thoracic radiotherapy (TRT), and single-agent chemotherapy. The guideline also discusses management of elderly patients based on performance status. Outcomes of interest include survival (median, overall, and progression-free), performance status, response rate, and toxicity.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with a positive diagnosis for cervical cancer. The guideline examines diagnosis and staging, and provides treatment recommendations based on cancer stage. Specific recommendations are also provided for pregnant patients. Outcomes of interest include improved use of adjuvant post-operative radiotherapy based on pathological findings.
A clinical practice guideline for the management of patients with nonmuscle invasive bladder cancer, identified as stages Tis, Ta, and T1. The guideline examines adjuvant therapy, recurrence prevention, and appropriate follow-up, with specific focus on maintenance therapy and treatment failure. Outcomes of interest include improved recommendations for bacillus calmette-guerin therapy and its use in improved maintenance therapy.
This is a clinical practice guideline for adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline reviews evaluation and staging, treatment, and follow-up procedures. Management of recurrent disease is also discussed. Outcomes of interest include survival (overall, disease-free, and progression-free), overall response rate, and toxicity.
Developer organization: European Association of Urology
A clinical practice guideline for the management of renal cell carcinoma. The guideline examines updates existing guidelines on diagnosis, staging, treatment, and follow-up, specifically focusing on improved data assessment. Outcomes of interest include improved evidence for the use of nephron-sparing surgery and increased use of surveillance for elderly patients.
This is a clinical practice guideline for men with prostate cancer or suspected prostate cancer. The guideline provides an overview of early diagnostic and screening procedures, management and treatment options, and follow-up care for low-risk, intermediate-risk, and advanced disease. The guideline also reviews bone health and the use of bisphosphonates as treatment for castrate resistant disease. Outcomes of interest include mortality, quality of life, morbidity, treatment complications, and toxicity.
Developer organization: American College of Chest Physicians
A clinical practice guideline for the management of small cell and non-small cell lung cancer. The guideline examines treatment options, including chemotherapy and surgical resection, based on pathologic tumour stage and histopathologic features. Outcomes of interest include increased diagnostic accuracy for pleural-based malignancies and improved distinction between primary lung cancers and metastatic lung cancers.
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for patients with known or suspected lung cancer. The guideline examines initial evaluation through physical examination and function tests, and special considerations are made for distant metastases and paraneoplastic syndromes. Outcomes of interest include improved survival with more efficient timelines and increased treatment team diversity.
Developer organization: Italian Society of Colo-Rectal Surgery
A clinical practice guideline for patients with squamous anal carcinoma. The guideline examines diagnosis, staging, and treatment through concurrent radiotherapy and chemotherapy. Outcomes of interest include improved differential diagnosis and indications for surgical excision.
This is a clinical practice guideline for patients over the age of 18 with gastric cancer. The guideline discusses diagnostic work-up, staging, and treatment recommendations. Outcomes of interest include survival (overall and five-year progression-free), and side effects of therapy.
Developer organization: European Society of Gastrointestinal and Abdominal Radiology (ESGAR)
This clinical practice guideline reviews the use of MRI for primary clinical staging or restaging of rectal cancer. The guideline provides recommendations on MRI requirements and sequences, criteria for MRI assessment, and MRI reporting. Imaging techniques including endorectal ultrasound, computed tomography (CT), and positron emission tomography (PET) are also discussed.
Developer organization: Society of Obstetricians and Gynaecologists of Canada
This is a clinical practice guideline for women with possible endometrial cancer. The guideline reviews the epidemiology of endometrial cancer and provides recommendations on diagnostic workup. Diagnostic procedures include biopsy, hysteroscopy, dilation and curettage, pelvic ultrasound, CT scan, and MRI. Outcomes of interest include accuracy, sensitivity, and specificity of diagnostic tests.
Developer organization: European Thyroid Association
This clinical practice guideline examines the use of cervical ultrasound scanning (US) in the postoperative management of patients with differentiated thyroid cancer of follicular origin. Topics of interest include recommendations on US procedure including fine needle aspiration technique, differentiation of benign and pathological US patterns, and indications for cervical ultrasound, US-FNA, and in situ biological marker assessment. New methods for preoperative localization of cervical recurrence and alternatives to surgical treatment of cervical recurrence are also discussed. Outcomes of interest include sensitivity, specificity, predictive value, and accuracy of ultrasound scanning.
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for women aged 19 or greater. The guideline reviews investigation of breast complaints and/or symptoms, diagnostic assessment stratified by age and risk, and management of common breast diseases. Referral criteria for genetic counselling is also discussed.
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for female patients with breast cancer. The guideline examines management from diagnosis to treatment, with specific recommendations for multiple diagnoses and supportive treatments. Outcomes of interest include improved psychological outcomes with reduced time to breast reconstruction and improved progression free survival through treatment concurrent bevacizumab and chemotherapy.
Developer organization: Italian Society of Hematology
A clinical practice guideline for the management of patients with follicular lymphoma. The guideline examines staging and management, primarily through chemoimmunotherapy and maintenance rituximab. Outcomes of interest include improved therapeutic options for relapsed patients and improved diagnostic predictors.
Developer organization: Association of Coloproctology of Great Britain and Ireland
This is a clinical practice guideline for patients with a malignant polyp. The guideline reviews topics such as colonoscopy and endoscopic technique for the removal of large adenomas, the histopathology of adenomas and polypoid carcinomas, how prognostic indicators influence the risk of residual cancer in the bowel wall or lymph nodes, and the likelihood of recurrence if additional treatment is not taken. As well, the benefits and harms of endoscopic resection are reviewed, and the role of endoscopic and radiological imaging in the assessment and follow up of malignant polyps is discussed. Outcomes of interest include risk of post-surgical morbidity and mortality, risk of recurrence, disease-specific survival, and nodal metastasis.
Developer organization: Society for Immunotherapy of Cancer
A clinical practice guideline for the treatment of cutaneous melanoma patients with tumour immunotherapy. The guideline examines the clinical application of immunotherapy with interferon‐α2b, pegylated‐interferon‐α2b, interleukin‐2 (IL‐2) and ipilimumab for high-risk, advanced-stage cancer. Outcomes of interest include decreasing the adverse effects of depression and improved therapeutic strategies with immunotherapy and standard radiation.
This is a clinical practice guideline for patients over 18 years of age with esophageal cancer, including both squamous cell and adenocarcinoma. The guideline provides recommendations on diagnostic work-up, staging, treatment options for potentially curable cancer, and management options for incurable cancer. Outcomes of interest include survival (overall, progression-free, 5-year), morbidity, toxicity, and rate of sudden death.
This is a clinical practice guideline for adults over 18 years of age with squamous cell carcinomas that arise in the anal canal. The guideline discusses diagnostic work-up, staging, and the goals of therapy and recommendations for both potentially curable, locally recurrent, and metastatic cancer of the anal canal. Follow-up care is also reviewed.
Developer organization: Japan Society of Hepatology
This is a clinical practice guideline for patients diagnosed with or at risk of developing hepatocellular carcinoma. The guideline reviews prevention, diagnosis and surveillance, surgery, percutaneous ablation therapy, transcatheter arterial chemoembolization (TACE), chemotherapy, and radiation therapy. Post-treatment surveillance, prevention of recurrence, and treatment of recurrent cancer are also reviewed. Outcomes of interest include survival, recurrence, disease progression, sensitivity, specificity, and predictive values of diagnostic tests, efficacy of surveillance and treatment techniques, surgical complications, and postoperative mortality.
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline reviews the use of pre- and post-operative therapy including chemotherapy and radiotherapy as treatment options. Outcomes of interest include survival (overall, cause-specific), quality of life, acute and late toxicities, and postoperative morbidity (within 30 days of surgery).
This is a clinical practice guideline for patients with testicular germ cell tumours. The guideline reviews diagnostic assessment, staging, management, and follow-up care for both seminoma and nonseminomas. Outcomes of interest include survival (overall, disease free), complete response rate, recurrence rates, and toxicity.
Developer organization: British Committee for Standards in Haematology
A clinical practice guideline for patients with primary refractory or relapsed Hodgkin lymphoma. The guideline examines the role of salvage therapy and autologous stem cell transplantation in eligible patients. Outcomes of interest include improved relapse confirmation and efficacy of first-line treatments.
Developer organization: American Society for Gastrointestinal Endoscopy
A clinical practice guideline for the assessment and treatment of esophageal cancer in adult patients. The guideline examines diagnosis and treatment, primarily through endoscopic biopsy and therapy. Outcomes of interest include an increased role for ablative techniques and improved palliation with stent methods.
Developer organization: American Society of Colon and Rectal Surgeons
A clinical practice guideline for the management of colorectal carcinoma. The guideline examines preoperative assessment, staging, surgical techniques, and operative considerations. Outcomes of interest include improved surgical management and reduced recurrence rate.
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for patients with known or suspected lung cancer. The guideline provides recommendations on staging of lung cancer including appropriate procedures for abnormal scan results. Several procedures are reviewed including CT, PET, endobronchial ultrasound-needle aspiration (EBUS-NA), endoscopic ultrasound (EUS)-NA, video-assisted thoracic surgery (VATS), and extended cervical mediastinoscopy. Outcomes of interest include morbidity, screening accuracy, and positive and negative predictive values of screening tests.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult patients with gestational trophoblastic neoplasia including invasive mole, gestational choriocarcinoma, and placental site trophoblastic tumours. The guideline examines management, including concurrent diagnoses and chemotherapy recommendations. Outcomes of interest include reduced congenital malformations in future pregnancies, and improved response rates in maintenance chemotherapy.
A clinical practice guideline for the management of patients diagnosed with adrenocortical carcinoma. The guideline examines the use of adjuvant mitotane therapy in resectable and unresectable carcinomas, and options for combination therapy. Outcomes of interest include lower rate of recurrence post-surgery and prolonged survival in children.
This is a clinical practice guideline for patients over 18 years of age with lymphoma. The guideline examines diagnostic assessment and staging procedures as well as treatment and management options. Follow-up and supportive care are also reviewed. Outcomes of interest include response rate (complete and overall), survival (progression-free and overall), time to disease progression, remission duration, freedom from treatment failure, impact of treatment on fertility, and toxicity from treatment.
This clinical practice guideline reviews management/treatment of and follow-up care for women with ovarian germ cell tumours. Topics of interest include the efficacy of four cycles of etoposide and cisplatin as compared to the standard therapy with three cycles of bleomycin, etoposide, and cisplatin. Supportive care for myelosuppression is also discussed. Outcomes of interest include survival, mortality, relapse, time to progression, treatment response, and treatment complications and side effects.
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, primary urethral carcinoma. The guideline reviews diagnostic assessment, staging, and treatment. Treatment options include penile-preserving and urethral-sparing surgery, urethrectomy, radiotherapy, cisplatinum-based chemotherapy, chemoradiotherapy, transurethral resection (TUR), Bacille-Calmette-Guérin (BCG), and cystoprostatectomy with extended pelvic lymphadenectomy. Outcomes of interest include survival, sensitivity of diagnostic tests, local cure rate, local recurrence rate, and local tumour control rate.
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, upper urinary tract urothelial carcinomas (UTUCs). The guideline reviews diagnostic assessment, staging, treatment, and follow-up. Treatment recommendations are provided based on whether the disease is localized or advanced, and include radical nephroureterectomy, conservative surgery, adjuvant topical agents, chemotherapy, and radiotherapy. Outcomes of interest include risk factors, sensitivity and specificity of diagnostic tests, survival (recurrence-free, disease-free, and overall), disease progression, morbidity, and mortality.
Developer organization: European Association of Urology
A clinical practice guideline for muscle-invasive and metastatic bladder cancer patients. The guideline examines management stages including diagnosis, staging, treatment, and follow up. Outcomes of interest include optimised treatment options for elderly patients and improved survival outcomes with pre-surgical neoadjuvant radiotherapy.
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for patients with unique forms of NSCLC that require special consideration, including patients with Pancoast tumors, T4 N0,1 M0 central tumours, chest wall involvement, additional pulmonary tumour nodules, synchronous and metachronous second primary lung cancers (SPLCs), multifocal lung cancer (MFLC), and solitary metastases. Diagnostic and staging procedures are reviewed and recommendations are made for treatment options including surgical resection, chemotherapy, and radiotherapy. Outcomes of interest include 5-year survival, mortality, accuracy of treatment procedures, complications, mortality, and cost-effectiveness.
A clinical practice guideline for patients with gastric cancers. The guideline examines diagnosis and management, including regional and resource-based recommendations. Outcomes of interest include increased HER2 testing and increased post-operative chemotherapy for palliative patients.
This is a clinical practice guideline for patients over 18 years of age with early stage rectal cancer. The guideline reviews diagnostic work-up, staging, and treatment options including surgical resection and chemotherapy.
This is a clinical practice guideline for adults over 18 years of age with early stage colon cancer. The guideline provides recommendations on diagnostic work-up, staging, and treatment including a review of recommended chemotherapy regimes.
A clinical practice guideline for patients with biliary tract cancer. The guideline examines management, with specific focus on surgical resection for potentially resectable disease and palliative radiotherapy for unresectable disease. Outcomes of interest include improved recommendations for establishing resectability and reductions in endoscopic retrograde cholangiopancreatogram.
Developer organization: College of American Pathologists
This clinical practice guideline provides recommendations on validation requirements for whole slide imaging (WSI) systems to be used for diagnostic purposes in pathology. Recommendations include those on sample size, revalidation, washout period, documenting the validation process, and pathologist training. Outcomes of interest include correlation between WSI and glass slides with respect to accuracy, concordance, average diagnostic certainty, sensitivity, and specificity, in the context of validation requirements.
A clinical practice guideline for patients undergoing surgery for gastric cancer. The guideline examines surgical quality with specific focus on staging and surgical margins. Outcomes of interest include improved recommendations for multiorgan resection and improved staging-based resection choice.
Developer organization: International Society of Urological Pathology
This clinical practice guideline provides recommendations on the classification, prognostic factors, staging, and molecular biology of adult renal tumours. Tumour morphotype, sarcomatoid and rhabdoid differentiation, tumour necrosis, tumour grading, and microscopic venous invasion are discussed.
Developer organization: Society of Obstetricians and Gynaecologists of Canada
This is a clinical practice guideline for patients with endometrial cancer. The guideline discusses limited surgery and extended surgical staging, with recommendations on the extent of surgery depending on low- or high-risk disease type. Outcomes of interest include prognostic value, survival (disease-free and overall), and negative predictive value and sensitivity of staging techniques.
A clinical practice guideline for patients with malignant melanoma. The guideline examines management from diagnosis to follow-up, including referral processes, recommendations for pregnant patients, and supportive care. Outcomes of interest include improved recommendations for the timing and efficacy of sentinel lymph node biopsy, which is generally recommended as a first-line staging tool.
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for patients with small cell and non-small cell lung cancer. The guideline examines lung cancer management from diagnosis to follow up, including considerations of tumour and organ risks. Outcomes of interest include increased treatment effectiveness through concurrent chemotherapy and improved post-operative management recommendations.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult patients with squamous cell carcinoma of the vulva. The guideline examines management of vulvar cancer based on staging, and follow-up protocols. Outcomes of interest include endorsement of sentinel lymph node biopsy as a standard of care and improved referral recommendations.
Developer organization: British Committee for Standards in Haematology
This clinical practice guideline discusses diagnosis and management and treatment of patients with suspected or confirmed multiple myeloma. Diagnostic procedures are recommended and treatment options outlined, including chemotherapy, induction therapy, high-dose therapy and autologous stem cell transplantation (ASCT), and allogeneic stem cell transplantation (AlloSCT). The guideline also discusses maintenance therapy and supportive interventions for common complications resulting from myeloma or its treatment. Outcomes of interest include treatment response rate, survival, toxicity, quality of life, and treatment-related mortality.
This is a clinical practice guideline for patients 18 years of age or older with malignant melanoma. The guideline reviews clinical presentation and preliminary work-up for malignant melanoma as well as additional work-up depending on stage. Outcomes of interest include cost-effectiveness, and specificity and sensitivity of diagnostic procedures.
A clinical practice guideline for patients presenting with a mole or lesion that is suspicious for melanoma. The guideline examines biopsy techniques and diagnostic elements. Outcomes of interest include reducing misdiagnosis and testing inaccuracy.
Developer organization: American Society for Gastrointestinal Endoscopy
A clinical practice guideline for the use of gastrointestinal endoscopy in the staging and management of colorectal cancer in adult patients. The guideline examines staging, endoscopic management, and endoscopic resection in colonic obstructions and colorectal neoplasia. Outcomes of interest include improved differentiation between benign and malignant lymph nodes through endoscopic ultrasound-guided fine-needle aspiration.
Developer organization: Society of Thoracic Surgeons
This clinical practice guideline reviews the diagnosis and staging of esophageal cancer in adult patients. Procedures including flexible endoscopy with biopsy, CT, PET, endoscopic ultrasonography (EUS), Endoscopic mucosal resection (EMR), and laparoscopy are discussed. Outcomes of interest include sensitivity, specificity, and accuracy of diagnostic procedures.
Developer organization: European Association of Urology
A clinical practice guideline for the management of prostate cancer in adult males. The guideline examines the screening, diagnosis, treatment, and palliative options for prostate cancer patients, with reference to multiple options following failed curative intent treatments. Outcomes of interest include improved screening to rule out radical treatment and treatment deferral.
This is a clinical practice guideline for patients diagnosed with or at risk of developing epithelial ovarian cancer. The guideline reviews risk factors and provides recommendations on screening, diagnosis, surgical management, chemotherapy, and follow-up care. Special topics of consideration include the role of prophylactic salpingo-oophorectomy in screening, and management of malignant bowel obstruction in relapsed disease. Outcomes of interest include diagnostic test accuracy, survival (overall and disease-free), response rates, quality of life, and adverse effects of treatment.
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline for patients with mantle cell lymphoma. The guideline provides recommendations on diagnostic procedures, initial investigations, and treatment including first- and second-line management. Outcomes of interest include survival (progression and overall) and overall response rate to treatment.
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for Hodgkin's lymphoma patients in Saskatchewan. The guideline provides an overview of procedures related to diagnosis, staging, treatment, relapse treatment, and follow-up for Hodgkin's lymphoma. The guideline considers both remission and palliative treatment outcomes.
This is a clinical practice guideline on the diagnosis, staging, treatment, supportive interventions and follow-up care for adult patients with lymphoma. Staging techniques include immunohistochemical and fluorescence in situ hybridization (FISH) testing. Treatment and management options are discussed for Hodgkin and non-Hodgkin lymphomas, with recommendations based on cancer type and stage. Outcomes of interest include response rates, disease progression, survival, remission, and adverse effects.
This is a clinical practice guideline on the management of chronic myeloid leukemia in patients over 18 years of age. The guideline provides recommendations on staging and prognosis, diagnosis and baseline investigations, treatment options, and treatment response assessment. First and second generation TKI's, induction chemotherapy, allogeneic stem cell transplant, and interferon-a are all discussed as treatment options. Outcomes of interest include treatment efficacy, survival rate, disease progression, and adverse events.
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for the management of bone sarcomas including osteosarcoma, Ewing sarcoma, high-grade spindle/pleomorphic sarcomas of bone, chondrosarcoma, giant cell tumour of bone, and chordoma. The guideline provides recommendations on diagnostic assessment and staging, treatment, and follow-up care. Outcomes of interest include incidence of subtypes, local recurrence, and survival.
A clinical practice guideline for patients with thymic neoplasms. The guideline examines staging based treatment and follow up, focusing on surgical resection and postoperative radiotherapy. Outcomes of interest include reduced relapse and improved multimodal treatment regimens.
Developer organization: French Otorhinolaryngology - Head and Neck Surgery Society (SFORL)
This clinical practice guideline is part 3 of a 3 part series on the initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding nasopharynx). This guideline discusses screening, assessment and initial management of risk factors (smoking, alcohol, HPV), frequent medical comorbidities, nutritional status, social and psychological status, dental status, pain and possible anemia. The guideline also outlines chemotherapy work-up and work-up for microanastomosed free-flap cervicofacial reconstruction.
A clinical practice and professional guideline that seeks to establish a standard of care in Alberta for the management of axillary nodes in patients with newly diagnosed, early-stage breast cancer. The guideline compares sentinel lymph node biopsy (SLNB) with axillary lymph node dissection (ALND) for axillary staging, and provides recommendations for management of positive biopsy results. Technical and operational considerations are also discussed. Outcomes of interest include false-negative rates and survival.
Developer organization: French Otorhinolaryngology - Head and Neck Surgery Society (SFORL)
This clinical practice guideline is part 1 of a 3 part series on the initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding nasopharynx). This guideline discusses locoregional extension assessment and provides recommendations on clinical and endoscopic examination, imaging assessment, and time to treatment. Outcomes of interest include effectiveness of diagnostic aids in early detection, sensitivity and specificity of imaging techniques, and impact of interval to initiation of radiation therapy on results.
Developer organization: Integraal Kankercentrum Nederland
A clinical practice guideline for patients with melanoma of the skin. The guideline examines management and daily practice support for melanoma, including genetic risk-based screening, and appropriate excision. Outcomes of interest include reduced recurrence through larger excision margins and improved prevention recommendations.
Developer organization: American Society of Colon and Rectal Surgeons
A clinical practice guideline for patients with squamous-cell carcinoma of the anus. The guideline examines pre-treatment evaluation, treatment, and post-treatment surveillance, with specific recommendations for HIV-positive patients. Outcomes of interest include increased support for intensity-modulated radiation therapy-based chemoradiotherapy as a primary treatment, and specifically for HIV-positive patients with higher toxicity risks.
Developer organization: European Organisation for Research and Treatment of Cancer
A clinical practice guideline for gastroesophageal cancer treatment and staging recommendations. The guideline examines surgical and systemic therapy treatment options for primary care in a variety of gastroesophageal cancers. Outcomes of interest include use of staging endosonography and laparoscopy and primary treatment strategies. The use of endosonography, laparoscopy, and PET-CT scans in routine staging is also examined.
Developer organization: European Society for Medical Oncology
This clinical practice guideline is for cancer patients who are being considered for anti-TNF-alpha therapy. Treatment related infections are reviewed, including tuberculosis, human papilloma virus, hepatitis B and C, Varicella zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus and human immunodeficiency virus. The guideline discusses risk factors for developing infection, and provides recommendations on preventative measures such as vaccination for at-risk individuals.
Developer organization: British Committee for Standards in Haematology
This clinical practice guideline reviews the diagnosis, clinical and laboratory evaluation, and treatment of chronic lymphocytic leukaemia (CLL). Autoimmune complications in CLL and supportive care are also discussed. Outcomes of interest include partial response and complete response to treatment, and overall and progression-free survival.
A clinical practice guideline summarizing the use of positron emission tomography (PET) in the diagnosis, staging, and treatment of patients with cancer. The guideline provides literature updates on PET use for multiple types of cancer. Outcomes of interest include recurrence times and safety outcomes.
This clinical practice guideline examines staging recommendations for determining extent of local tumour invasion and tumour spread in patients with bladder cancer. The guideline examines the use of CT and MRI imaging, both comparatively and consecutively, in the pelvic region.
A clinical practice guideline for the use of positron emission tomography PET scans in patients in adult patients with lung cancer. The guideline examines the use of PET scans in the diagnosis and staging of solitary pulmonary nodules, small-cell lung cancer and non-small-cell lung cancer. Outcomes of interest include imaging accuracy and the impact of new PET scan technologies.
Developer organization: Japanese Urological Association
A clinical practice guideline for patients with renal cell carcinoma. The guideline examines diagnosis, risk factors, and treatment via surgery and systemic therapies. Molecular targeted therapy and the use of imaging for staging purposes are also considered.
Developer organization: European Society for Medical Oncology
A clinical practice guideline for the management of patients with soft tissue and visceral sarcomas. The guideline examines surgical intervention with systemic therapies, following diagnosis and staging through imaging and core needle biopsies. Considerations include risk of relapse and differences in treatment for special presentations.
A clinical practice guideline for the management of patients with renal cell carcinoma. The guideline examines diagnostic assessment and appropriate first and second line therapies, including surgical and minimally invasive therapies. Outcomes of interest include increased assessment for treatment tolerance, and improved median survival.
Developer organization: Barrett's Dysplasia and Cancer Taskforce (BAD CAT)
This clinical practice guideline provides recommendations on the management of patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD), high-grade dysplasia (HGD), or early- stage esophageal adenocarcinoma (EA). Diagnosis of BE and HGD, risk factors for EA and surveillance of at-risk patients, and treatment of HGD and early EA are discussed.
This is a professional guideline that provides recommendations on the organization and delivery of health-care services for head and neck cancer patients in Alberta. The guideline outlines the professional health-care team involved in the treatment of head and neck cancer patients, including their roles and minimum required qualifications. It also provides guidance on minimum infrastructure requirements, optimal cancer centre and team member volumes, and wait times to care from referral to initiation of curative treatment.
This is a clinical practice guideline for women with gestational trophoblastic neoplasia, including invasive mole, choriocarcinoma, and placental site trophoblastic tumour. The guideline provides recommendations on diagnostic assessment, staging, prognostic scoring, treatment, and follow-up procedures. Outcomes of interest include diagnostic accuracy, complete response rate, survival rate, and risk of subsequent abnormal pregnancy.
Developer organization: European Association of Urology
A clinical practice guideline for chemotherapy treatment in patients with bladder cancer. The guideline examines the risks and benefits of adjuvant and neoadjuvant chemotherapy, and potential confounding factors including surgery. Outcomes of interest include improved treatment for patients with lymph node involvement and reduced staging discrepancies.
Developer organization: French Otorhinolaryngology - Head and Neck Surgery Society (SFORL)
This clinical practice guideline is part 2 of a 3 part series on the initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding nasopharynx). The guideline discusses remote extension assessment (exploration for remote metastasis) and exploration for secondary synchronous locations outside of the upper aero digestive tract. Outcomes of interest include metastatic risk, prognostic factors, and sensitivity and specificity of imaging techniques.
Developer organization: American Society of Colon and Rectal Surgeons
A clinical practice guideline for patients with colon cancer. The guideline examines risk assessment and treatment, primarily through surgical resection. Outcomes of interest include improved prediction of outcomes through histologic grading and reduced surgical morbidity in palliative procedures.
This is a clinical practice guideline for the management of patients with multiple endocrine neoplasia (MEN) type 1 (MEN1) and their families. Recommendations are provided for genetic testing and screening, diagnosis, and treatment of MEN1 related tumours. Organization of care is also discussed.
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for head and neck cancer patients (HNCPs) undergoing radiotherapy. The guideline reviews dysphagia mechanisms and causes in HNCPs and provides recommendations on the management of patients undergoing radiotherapy who have pre-treatment dysphagia or are at risk for dysphagia. The occurrence of dysphagia in post-surgical radiotherapy or after chemoradiotherapy is also discussed.
Developer organization: British Society of Gastroenterology
This is a clinical practice guideline for the management of patients with cholagiocarcinoma or suspected cholagiocarcinoma. The guideline discusses risk factors, diagnosis and staging, and treatment options. Outcomes of interest include survival, time-to-progression, tumour control rate, and rate of surgical complications.
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for the diagnosis and treatment of patients with myelodysplastic syndrome. The guideline examines the presentation of myelodysplastic syndrome in older and elderly patients, and treatment options for lower and higher risk patients. Outcomes of interest include improved quality of life, including prolonged survival, and improved blood cytopenia.
A clinical practice guideline for the use of MRI in breast cancer screening for patients who have hereditary risk, or have had previous radiation. The guideline examines indications and contraindications for breast MRI in screening, assessment, evaluation of treatment, and follow up. Outcomes of interest include MRI sensitivity and specificity.
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
A clinical practice guideline for the management of patients with premalignant atrophic gastritis, intestinal metaplasia, and epithelial dysplasia at risk for gastric cancers. The guideline makes recommendations for staging, treatment, and follow-up for precancerous gastric conditions to improve the diagnosis of early stage cancer. Outcomes of interest include Helicobacter pylori eradication, pharmacological options, and an analysis of patient benefits in terms of cost-effectiveness.
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline on the diagnosis and laboratory investigation, treatment management, follow-up and monitoring of patients with follicular lymphoma (FL). Topics of interest include the use of prognostic scoring systems and the role of autologous and allogeneic transplant in the treatment of FL. Outcomes of interest include survival (overall, event-free and progression free), relapse risk, transplant-related mortality and overall response rate to treatment.
Developer organization: UK and Ireland Neuroendocrine Tumour Society
This is a clinical practice guideline for patients with gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Genetic risk factors, diagnostic assessment including imaging and pathology, and treatment are discussed. Special topics of interest include genetic risk factors and association of NETs with carcinoid heart disease (CHD). Outcomes of interest include survival rates, sensitivity of diagnostic testing procedures, adverse effects and quality of life.
A clinical practice guideline for patients with non-small cell lung cancer. The guideline examines diagnosis, treatment, and follow up, with a focus on surgical resection as the preferred therapy. Outcomes of interest include fewer complications through video-assisted thoracic surgery and improved control with stereotactic body radiation therapy.
A clinical practice guideline for asymptomatic patients with recently diagnosed primary breast cancer who have already undergone surgical resection. Recommendations are provided for staging investigations, and procedures including bilateral mammography, biopsy, ultrasound, and MRI are discussed.
A clinical practice guideline for the use of positron emission tomography (PET) in the diagnosis, staging, and treatment of patients with cancer. This guideline provides an updated literature review for multiple adult cancers. Outcomes of interest include recurrence and safety outcomes.
Developer organization: European Lung Cancer Working Party
This clinical practice guideline examines the use of early intermediate criteria (surrogate markers) to predict treatment efficacy in patients with lung cancer including SCLC, NSCLC, and other histological types of pulmonary malignancies. The guideline examines the validity of several intermediate markers as surrogate end-points in lung cancer including time to progression, objective morphological response to chemotherapy, quality of life, downstaging after induction chemotherapy, and metabolic response.
Developer organization: European Respiratory Society
A clinical practice guideline for the diagnosis, staging, and treatment of predominantly male patients with malignant pleural mesothelioma. The guideline examines the epidemiology of malignant mesothelioma and considers staging and treatment options including surgery, radiotherapy, and chemotherapy. Guidance is also provided for tumour response evaluation and management of symptoms.
